0001752724-21-258553.txt : 20211124 0001752724-21-258553.hdr.sgml : 20211124 20211124164944 ACCESSION NUMBER: 0001752724-21-258553 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211124 PERIOD START: 20211231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: T. Rowe Price Health Sciences Fund, Inc. CENTRAL INDEX KEY: 0001002624 IRS NUMBER: 521952906 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-07381 FILM NUMBER: 211447494 BUSINESS ADDRESS: STREET 1: 100 EAST PRATT STREET CITY: BALTIMORE STATE: MD ZIP: 21202 BUSINESS PHONE: 410-345-2000 MAIL ADDRESS: STREET 1: 100 EAST PRATT STREET CITY: BALTIMORE STATE: MD ZIP: 21202 FORMER COMPANY: FORMER CONFORMED NAME: PRICE T ROWE HEALTH SCIENCES FUND INC DATE OF NAME CHANGE: 19980513 FORMER COMPANY: FORMER CONFORMED NAME: PRICE T ROWE HEALTH & LIFE SCIENCES FUND INC DATE OF NAME CHANGE: 19951023 0001002624 S000002088 T. Rowe Price Health Sciences Fund, Inc. C000005456 T. Rowe Price Health Sciences Fund, Inc. PRHSX C000169937 T. Rowe Price Health Sciences Fund-I Class THISX NPORT-P 1 primary_doc.xml NPORT-P false 0001002624 XXXXXXXX S000002088 C000005456 C000169937 T. ROWE PRICE HEALTH SCIENCES FUND, INC. 811-07381 0001002624 549300ELV6FPY6UQBJ78 100 East Pratt Street Baltimore 21202 410-345-2000 T. Rowe Price Health Sciences Fund, Inc. S000002088 66LP7EMLZS5S33LWIH41 2021-12-31 2021-09-30 N 19376329627.72 81576711.52 19294752916.20 775903001.81000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 14154210.00000000 0.00000000 0.02000000 N Zimmer Biomet Holdings Inc 2P2YLDVPES3BXQ1FRB91 Zimmer Biomet Holdings Inc 98956P102 444930.00000000 NS USD 65119954.80000000 0.337500848457 Long EC CORP US N 1 N N N GINGKO BIOWORKS HOLDINGS N/A GINGKO BIOWORKS HOLDINGS 000000000 547946.00000000 NS USD 6033159.43000000 0.031268394346 Long EC CORP US Y 2 N N N Longboard Pharmaceuticals Inc N/A Longboard Pharmaceuticals Inc 54300N103 780535.00000000 NS USD 6954566.85000000 0.036043824350 Long EC CORP US N 1 N N N Merck & Co Inc 4YV9Y5M8S0BRK1RP0397 Merck & Co Inc 58933Y105 4262646.00000000 NS USD 320167341.06000000 1.659349266873 Long EC CORP US N 1 N N N Evotec SE 529900F9KI6OYITO9B12 Evotec SE 000000000 889119.00000000 NS 42159335.97000000 0.218501559222 Long EC CORP DE N 2 N N N Cerevel Therapeutics Holdings N/A Cerevel Therapeutics Holdings Inc 15678U128 1769216.00000000 NS USD 52191872.00000000 0.270497747375 Long EC CORP US N 1 N N N BECTON DICKINSON AND CO ICE2EP6D98PQUILVRZ91 BECTON DICKINSON AND CO 075887109 980714.00000000 NS USD 241079115.48000000 1.249454276647 Long EC CORP US N 1 N N N Sartorius AG 529900EQV2DY4FOAMU38 Sartorius AG 000000000 196084.00000000 NS 124828804.68000000 0.646957259427 Long EP CORP DE N 2 N N N COLOR GENOMICS SER D CVT PFD STOCK PP N/A COLOR GENOMICS SER D CVT PFD STOCK PP 000000000 296922.00000000 NS USD 13596058.38000000 0.070465055650 Long EP CORP US Y 3 N N N RAPID MICRO BIOSYSTEMS INC N/A RAPID MICRO BIOSYSTEMS INC 000000000 370289.00000000 NS USD 6497275.94000000 0.033673797058 Long EC CORP US Y 2 N N N Penumbra Inc 549300RGE06P3ECANU72 Penumbra Inc 70975L107 546904.00000000 NS USD 145749916.00000000 0.755386278502 Long EC CORP US N 1 N N N Option Care Health Inc 549300DI3Q5ACSYJRI17 Option Care Health Inc 68404L201 1666189.00000000 NS USD 40421745.14000000 0.209496049602 Long EC CORP US N 1 N N N Health Sciences Acquisitions C N/A Health Sciences Acquisitions Corp 2 000000000 688861.00000000 NS USD 6812835.29000000 0.035309264231 Long EC CORP US N 1 N N N Stoke Therapeutics Inc 549300RD25SS2DIJHJ67 Stoke Therapeutics Inc 86150R107 254758.00000000 NS USD 6481043.52000000 0.033589668383 Long EC CORP US N 1 N N N Definitive Healthcare Corp N/A Definitive Healthcare Corp 24477E103 615230.00000000 NS USD 26350300.90000000 0.136567184946 Long EC CORP US N 1 N N N Ortho Clinical Diagnostics Hol N/A Ortho Clinical Diagnostics Holdings PLC 000000000 3577780.00000000 NS USD 66117374.40000000 0.342670231057 Long EC CORP US N 1 N N N PAX LABS CLASS A COMMON PP N/A PAX LABS CLASS A COMMON PP 000000000 8397988.00000000 NS USD 10665444.76000000 0.055276399787 Long EC CORP US Y 3 N N N Moderna Inc 549300EI6OKH5K5Q2G38 Moderna Inc 60770K107 1276162.00000000 NS USD 491143707.32000000 2.545478086467 Long EC CORP US N 1 N N N Phreesia Inc 5493000HHF8NU4QOCG53 Phreesia Inc 71944F106 1174872.00000000 NS USD 72489602.40000000 0.375695935132 Long EC CORP US N 1 N N N Bruker Corp LEBZ6VLQ6I8XB1NHVY15 Bruker Corp 116794108 2029650.00000000 NS USD 158515665.00000000 0.821548043079 Long EC CORP US N 1 N N N Lantheus Holdings Inc 5299005HUB5IOJGO7S39 Lantheus Holdings Inc 516544103 878190.00000000 NS USD 22551919.20000000 0.116881098700 Long EC CORP US N 1 N N N Ginkgo Bioworks Holdings, Inc N/A Ginkgo Bioworks Holdings, Inc 000000000 7090407.00000000 NS USD 78068926.27000000 0.404612210423 Long EC CORP US Y 2 N N N Generation Bio Co N/A Generation Bio Co 37148K100 1736219.00000000 NS USD 43527010.33000000 0.225589881969 Long EC CORP US N 1 N N N RAPT Therapeutics Inc 549300MB473BIU78ES48 RAPT Therapeutics Inc 75382E109 738777.00000000 NS USD 22939025.85000000 0.118887378084 Long EC CORP US N 1 N N N Dexcom Inc 549300YSK3QDSFR5EU59 Dexcom Inc 252131107 284357.00000000 NS USD 155503469.02000000 0.805936565735 Long EC CORP US N 1 N N N Zai Lab Ltd 549300P2UYQ9U5LY1T58 Zai Lab Ltd 98887Q104 436922.00000000 NS USD 46047209.58000000 0.238651460218 Long EC CORP CN N 1 N N N Humana Inc 529900YLDW34GJAO4J06 Humana Inc 444859102 823804.00000000 NS USD 320583326.60000000 1.661505218503 Long EC CORP US N 1 N N N Acceleron Pharma Inc 529900TQRID2UY164805 Acceleron Pharma Inc 00434H108 1692703.00000000 NS USD 291314186.30000000 1.509810400605 Long EC CORP US N 1 N N N GENESIS THERA SER A CVT PFD STOCK PP N/A GENESIS THERA SER A CVT PFD STOCK PP 000000000 829412.00000000 NS USD 4236304.73000000 0.021955734537 Long EP CORP US Y 3 N N N Nevro Corp 254900SH91I4BOYKUE38 Nevro Corp 64157F103 245132.00000000 NS USD 28528462.16000000 0.147856063686 Long EC CORP US N 1 N N N Agiliti Inc N/A Agiliti Inc 00848J104 1604221.00000000 NS USD 30544367.84000000 0.158304011316 Long EC CORP US N 1 N N N PROCEPT BioRobotics Corp N/A PROCEPT BioRobotics Corp 74276L105 268312.00000000 NS USD 10236102.80000000 0.053051225089 Long EC CORP US N 1 N N N NUTCRACKER THERA SER C CVT PFD STOCK PP N/A NUTCRACKER THERA SER C CVT PFD STOCK PP 000000000 1027785.00000000 NS USD 11050024.87000000 0.057269584731 Long EP CORP US Y 3 N N N Avidity Biosciences Inc N/A Avidity Biosciences Inc 05370A108 963638.00000000 NS USD 23734403.94000000 0.123009628799 Long EC CORP US N 1 N N N SPAC CMLT/EQRX PIPE COMMIT PP N/A SPAC CMLT/EQRX PIPE COMMIT PP 000000000 884467.00000000 NS USD 7896521.38000000 0.040925745016 Long EC CORP US N 2 N N N Burning Rock Biotech Ltd N/A Burning Rock Biotech Ltd 12233L107 456624.00000000 NS USD 8164437.12000000 0.042314286974 Long EC CORP CN N 1 N N N Genmab A/S 529900MTJPDPE4MHJ122 Genmab A/S 372303206 45647.00000000 NS USD 1994773.90000000 0.010338426766 Long EC CORP DK N 1 N N N DELFI DIAGNOSTICS SR A CVT PFD STOCK PP N/A DELFI DIAGNOSTICS SR A CVT PFD STOCK PP 000000000 2152801.00000000 NS USD 4464909.27000000 0.023140536131 Long EP CORP US Y 3 N N N Acerta Future Payments PP N/A Acerta Future Payments PP 000000000 25372878.73000000 NS USD 22772158.66000000 0.118022546123 Long EC CORP US Y 3 N N N REFLEXION MEDICAL INC N/A REFLEXION MEDICAL INC CVT PFD SR C PP 000000000 2507885.00000000 NS USD 5717639.24000000 0.029633130130 Long EP CORP US Y 3 N N N agilon health Inc N/A agilon health Inc 00857U107 936437.00000000 NS USD 24544013.77000000 0.127205639152 Long EC CORP US N 1 N N N Seres Therapeutics Inc 549300GMXBE5NUWISF13 Seres Therapeutics Inc 81750R102 471039.00000000 NS USD 3278431.44000000 0.016991310820 Long EC CORP US N 1 N N N IMAGO BIOSCIENCES INC N/A IMAGO BIOSCIENCES INC 000000000 529300.00000000 NS USD 10071785.05000000 0.052199606254 Long EC CORP US Y 2 N N N Denali Therapeutics Inc 549300ZTQ2HO18L3Q830 Denali Therapeutics Inc 24823R105 1432855.00000000 NS USD 72287534.75000000 0.374648667769 Long EC CORP US N 1 N N N Oak Street Health Inc 2549007CJE6GSEURLA30 Oak Street Health Inc 67181A107 465354.00000000 NS USD 19791505.62000000 0.102574548147 Long EC CORP US N 1 N N N Doximity, Inc N/A Doximity, Inc 000000000 2071266.00000000 NS USD 158793607.89000000 0.822988553311 Long EC CORP US Y 2 N N N LARONDE SERIES B CVT PFD STOCK PP N/A LARONDE SERIES B CVT PFD STOCK PP 000000000 1169887.00000000 NS USD 32756836.00000000 0.169770694355 Long EP CORP US Y 3 N N N Novavax Inc 529900J4GJHPEPQ23205 Novavax Inc 670002401 291207.00000000 NS USD 60370123.17000000 0.312883629203 Long EC CORP US N 1 N N N Berkeley Lights Inc 549300LTLRE4N65CD358 Berkeley Lights Inc 084310101 331312.00000000 NS USD 6480462.72000000 0.033586658238 Long EC CORP US N 1 N N N VIVIDION THERAPEUTICS MILESTONE PAYMENT N/A VIVIDION THERAPEUTICS MILESTONE PAYMENT 000000000 2328481.81000000 NS USD 1137696.21000000 0.005896402068 Long EC CORP US Y 3 N N N IVERIC bio Inc 549300GZXI59U71XPM70 IVERIC bio Inc 46583P102 2537772.00000000 NS USD 41213417.28000000 0.213599093281 Long EC CORP US N 1 N N N Sarepta Therapeutics Inc 549300IKDPIED8J8IG21 Sarepta Therapeutics Inc 803607100 279992.00000000 NS USD 25893660.16000000 0.134200527327 Long EC CORP US N 1 N N N TEMPUS LAB SERIES G CVT PFD N/A TEMPUS LAB SERIES G CVT PFD 000000000 111715.00000000 NS USD 6461584.43000000 0.033488816664 Long EP CORP US Y 3 N N N Insulet Corp 549300TZTYD2PYN92D43 Insulet Corp 45784P101 313825.00000000 NS USD 89198479.75000000 0.462293972549 Long EC CORP US N 1 N N N Eli Lilly & Co FRDRIPF3EKNDJ2CQJL29 Eli Lilly & Co 532457108 2243718.00000000 NS USD 518411043.90000000 2.686798043755 Long EC CORP US N 1 N N N VIVIDION THERAPEUTICS MILESTONE PAYMENT N/A VIVIDION THERAPEUTICS MILESTONE PAYMENT 000000000 1746361.36000000 NS USD 1023891.67000000 0.005306580884 Long EC CORP US Y 3 N N N AC Immune SA 967600VLQ0ZC2HSOG765 AC Immune SA 000000000 335619.00000000 NS USD 2252003.49000000 0.011671585014 Long EC CORP CH N 1 N N N Karuna Therapeutics Inc N/A Karuna Therapeutics Inc 48576A100 427366.00000000 NS USD 52279682.78000000 0.270952849238 Long EC CORP US N 1 N N N Agilent Technologies Inc QUIX8Y7A2WP0XRMW7G29 Agilent Technologies Inc 00846U101 2218531.00000000 NS USD 349485188.43000000 1.811296521639 Long EC CORP US N 1 N N N Lonza Group AG 549300EFW4H2TCZ71055 Lonza Group AG 000000000 77808.00000000 NS 58364544.19000000 0.302489202341 Long EC CORP CH N 2 N N N Incyte Corp 549300Z4WN6JVZ3T4680 Incyte Corp 45337C102 2323016.00000000 NS USD 159777040.48000000 0.828085444648 Long EC CORP US N 1 N N N CureVac NV 724500BUT8GAG9LMYN56 CureVac NV 000000000 405872.00000000 NS USD 22168728.64000000 0.114895115455 Long EC CORP DE N 1 N N N Neurocrine Biosciences Inc 549300FECER0XBN49756 Neurocrine Biosciences Inc 64125C109 365109.00000000 NS USD 35017604.19000000 0.181487704673 Long EC CORP US N 1 N N N T. ROWE PRICE GOVERNMENT RESERVE FUND 5493007QR86JJLYO6D96 T. ROWE PRICE GOVERNMENT RESERVE FUND 000000000 34552325.04000000 NS USD 34552325.04000000 0.179076276281 Long STIV RF US N 1 N N N Relay Therapeutics Inc N/A Relay Therapeutics Inc 75943R102 312846.00000000 NS USD 9864034.38000000 0.051122885184 Long EC CORP US N 1 N N N Scholar Rock Holding Corp 549300Z1FLPGL4OWJ459 Scholar Rock Holding Corp 80706P103 952830.00000000 NS USD 31462446.60000000 0.163062189687 Long EC CORP US N 1 N N N Alector Inc 549300Z8RQOIY1JMHC25 Alector Inc 014442107 513521.00000000 NS USD 11718549.22000000 0.060734383440 Long EC CORP US N 1 N N N TEMPUS LABS INC N/A TEMPUS LABS INC CVT PFD SR D PP 000000000 946886.00000000 NS USD 52999860.70000000 0.274685355807 Long EP CORP US Y 3 N N N Enanta Pharmaceuticals Inc 529900SSN4DODDQSN594 Enanta Pharmaceuticals Inc 29251M106 220225.00000000 NS USD 12510982.25000000 0.064841370627 Long EC CORP US N 1 N N N Accolade Inc 549300PHKG8J7A22NF08 Accolade Inc 00437E102 444589.00000000 NS USD 18748318.13000000 0.097167961732 Long EC CORP US N 1 N N N EXACT SCIENCES FDA MILESTONE PP N/A EXACT SCIENCES FDA MILESTONE PP 000000000 1863135.85000000 NS USD 1490508.68000000 0.007724943078 Long EC CORP US Y 3 N N N Replimune Group Inc 549300AY704NEIRC4K64 Replimune Group Inc 76029N106 1248619.00000000 NS USD 37009067.16000000 0.191808971696 Long EC CORP US N 1 N N N Protagonist Therapeutics Inc N/A Protagonist Therapeutics Inc 74366E102 388176.00000000 NS USD 6878478.72000000 0.035649478124 Long EC CORP US N 1 N N N THESEUS PHARMA SERIES B CVT PFD STOCK PP N/A THESEUS PHARMA SERIES B CVT PFD STOCK PP 000000000 514797.00000000 NS USD 5837797.98000000 0.030255883583 Long EP CORP US Y 2 N N N SOMALOGIC INC N/A SOMALOGIC INC 000000000 3873442.00000000 NS USD 45592349.06000000 0.236294029045 Long EC CORP US Y 2 N N N Abcam PLC 213800B9N83DSNT33F79 Abcam PLC 000000000 1474562.00000000 NS 29555220.27000000 0.153177500631 Long EC CORP GB N 2 N N N Pacific Biosciences of Califor N/A Pacific Biosciences of California Inc 69404D108 2701237.00000000 NS USD 69016605.35000000 0.357696238193 Long EC CORP US N 1 N N N PROGNOMIQ SER B CVT PFD STOCK N/A PROGNOMIQ SER B CVT PFD STOCK 000000000 3734140.00000000 NS USD 8532935.59000000 0.044224124698 Long EP CORP US Y 3 N N N REGENXBIO Inc 549300EOES47LATSET33 REGENXBIO Inc 75901B107 238760.00000000 NS USD 10008819.20000000 0.051873269605 Long EC CORP US N 1 N N N KARDIUM INC SER D-5 CVT PFD STOCK PP N/A KARDIUM INC SER D-5 CVT PFD STOCK PP 000000000 8849057.00000000 NS USD 8989226.06000000 0.046588966954 Long EP CORP US Y 3 N N N TREELINE BIO SER A CVT PFD STOCK PP N/A TREELINE BIO SER A CVT PFD STOCK PP 000000000 922369.00000000 NS USD 7219843.35000000 0.037418687771 Long EP CORP US Y 3 N N N Quanterix Corp N/A Quanterix Corp 74766Q101 596234.00000000 NS USD 29686490.86000000 0.153857844093 Long EC CORP US N 1 N N N FREENOME HOLDINGS SER C CVT PFD PP N/A FREENOME HOLDINGS SER C CVT PFD PP 000000000 928231.00000000 NS USD 6138670.07000000 0.031815230268 Long EP CORP US Y 3 N N N Series A-5 CVT Pfd N/A Series A-5 CVT Pfd 000000000 513797.00000000 NS USD 1174084.72000000 0.006084994843 Long EP CORP US Y 3 N N N Arvinas Inc N/A Arvinas Inc 04335A105 549763.00000000 NS USD 45179523.34000000 0.234154453991 Long EC CORP US N 1 N N N Apellis Pharmaceuticals Inc 254900HS0ZFRXXSB9D42 Apellis Pharmaceuticals Inc 03753U106 1237214.00000000 NS USD 40778573.44000000 0.211345403681 Long EC CORP US N 1 N N N Eisai Co Ltd 353800HDEE0ZYEX4QV91 Eisai Co Ltd 000000000 345800.00000000 NS 25903007.71000000 0.134248973399 Long EC CORP JP N 2 N N N Cigna Corp 549300VIWYMSIGT1U456 Cigna Corp 125523100 918399.00000000 NS USD 183826743.84000000 0.952729193467 Long EC CORP US N 1 N N N CARIS LIFE SER D CVT PFD STOCK PP N/A CARIS LIFE SER D CVT PFD STOCK PP 000000000 2280334.00000000 NS USD 18470705.40000000 0.095729162639 Long EP CORP US Y 3 N N N INTUITIVE SURGICAL INC 54930052SRG011710797 INTUITIVE SURGICAL INC 46120E602 738824.00000000 NS USD 734501879.60000000 3.806744158839 Long EC CORP US N 1 N N N HONOR TECHNOLOGY SER E CVT PFD STOCK PP N/A HONOR TECHNOLOGY SER E CVT PFD STOCK PP 000000000 2095807.00000000 NS USD 6625684.25000000 0.034339306021 Long EP CORP US Y 3 N N N ELEMENT BIOSCIENCES SER C CVT PFD STOCK N/A ELEMENT BIOSCIENCES SER C CVT PFD STOCK 000000000 861217.00000000 NS USD 17703779.50000000 0.091754372688 Long EP CORP US Y 3 N N N DICE Therapeutics Inc N/A DICE Therapeutics Inc 23345J104 474448.00000000 NS USD 15538172.00000000 0.080530557024 Long EC CORP US N 1 N N N PROCEPT BioRobotics, Inc. N/A PROCEPT BioRobotics, Inc. 000000000 694834.00000000 NS USD 25182521.25000000 0.130514867743 Long EC CORP US Y 2 N N N PROGENIC PHARMACEUTICALS CVR N/A PROGENIC PHARMACEUTICALS CVR 000000000 842223.00000000 NS USD 40847.82000000 0.000211704291 Long EC CORP US N 2 N N N Novocure Ltd 213800YPP55UMHWA4826 Novocure Ltd 000000000 563219.00000000 NS USD 65429151.23000000 0.339103338167 Long EC CORP JE N 1 N N N Ginkgo Bioworks Holdings Earn Out Shares $17.50 PP N/A Ginkgo Bioworks Holdings Earn Out Shares $17.50 PP 000000000 212706.00000000 NS USD 1638413.48000000 0.008491497595 Long EC CORP US Y 2 N N N Ginkgo Bioworks Holdings Earn Out Shares $12.50 PP N/A Ginkgo Bioworks Holdings Earn Out Shares $12.50 PP 000000000 212707.00000000 NS USD 1770313.35000000 0.009175102462 Long EC CORP US Y 2 N N N FLAME BIOSCIENCES INC PP N/A FLAME BIOSCIENCES INC PP 000000000 839721.00000000 NS USD 5500172.55000000 0.028506053297 Long EC CORP US Y 3 N N N uniQure NV N/A uniQure NV 000000000 416122.00000000 NS USD 13320065.22000000 0.069034650393 Long EC CORP NL N 1 N N N Xencor Inc 549300V5IF65437JKG30 Xencor Inc 98401F105 988502.00000000 NS USD 32284475.32000000 0.167322564119 Long EC CORP US N 1 N N N Prothena Corp PLC 5299009ZXQ8NIIJ8OL30 Prothena Corp PLC 000000000 1006244.00000000 NS USD 71674760.12000000 0.371472806266 Long EC CORP IE N 1 N N N Insmed Inc 529900Q55QAG41CCAC11 Insmed Inc 457669307 2287188.00000000 NS USD 62989157.52000000 0.326457445677 Long EC CORP US N 1 N N N Monte Rosa Therapeutics Inc N/A Monte Rosa Therapeutics Inc 61225M102 393209.00000000 NS USD 8760696.52000000 0.045404554067 Long EC CORP US N 1 N N N HONOR TECHNOLOGY SER D CVT PFD PP N/A HONOR TECHNOLOGY SER D CVT PFD PP 000000000 3130941.00000000 NS USD 9898156.88000000 0.051299733782 Long EP CORP US Y 3 N N N Ascendis Pharma A/S 549300B66JN3W3J8GH73 Ascendis Pharma A/S 04351P101 813997.00000000 NS USD 129742981.83000000 0.672426241442 Long EC CORP DK N 1 N N N Allogene Therapeutics Inc N/A Allogene Therapeutics Inc 019770106 1213740.00000000 NS USD 31193118.00000000 0.161666325220 Long EC CORP US N 1 N N N VIVIDION THERAPEUTICS MILESTONE PAYMENT 3 N/A VIVIDION THERAPEUTICS MILESTONE PAYMENT 3 000000000 1746361.36000000 NS USD 710594.44000000 0.003682837728 Long EC CORP US Y 3 N N N Quidel Corp 549300X2FQ6S98OQLQ46 Quidel Corp 74838J101 436942.00000000 NS USD 61674363.30000000 0.319643187802 Long EC CORP US N 1 N N N Akero Therapeutics Inc 549300SI3KG74LBE2955 Akero Therapeutics Inc 00973Y108 320250.00000000 NS USD 7157587.50000000 0.037096030879 Long EC CORP US N 1 N N N Alignment Healthcare Inc N/A Alignment Healthcare Inc 01625V104 2570009.00000000 NS USD 41068743.82000000 0.212849286012 Long EC CORP US N 1 N N N AbbVie Inc FR5LCKFTG8054YNNRU85 AbbVie Inc 00287Y109 2638952.00000000 NS USD 284663752.24000000 1.475342822353 Long EC CORP US N 1 N N N CAPSULE SERIES D CVT PFD STOCK PP N/A CAPSULE SERIES D CVT PFD STOCK PP 000000000 853213.00000000 NS USD 12364421.51000000 0.064081782045 Long EP CORP US Y 3 N N N Surgery Partners Inc 549300LC82HG33S19I03 Surgery Partners Inc 86881A100 823568.00000000 NS USD 34869869.12000000 0.180722029825 Long EC CORP US N 1 N N N COOPER COS INC/THE QJKMVPIGLH7530PCUE20 COOPER COS INC/THE 216648402 197335.00000000 NS USD 81560528.85000000 0.422708335287 Long EC CORP US N 1 N N N GENERATE BIO SER B CVT PFD STOCK PP N/A GENERATE BIO SER B CVT PFD STOCK PP 000000000 1864632.00000000 NS USD 22095889.20000000 0.114517606397 Long EP CORP US Y 3 N N N FREENOME HOLDINGS SER B CVT PFD PP N/A FREENOME HOLDINGS SER B CVT PFD PP 000000000 1558570.00000000 NS USD 10307290.98000000 0.053420176069 Long EP CORP US Y 3 N N N Kodiak Sciences Inc 254900IXI5NI8C9OQE24 Kodiak Sciences Inc 50015M109 1364585.00000000 NS USD 130972868.30000000 0.678800443150 Long EC CORP US N 1 N N N Regeneron Pharmaceuticals Inc 549300RCBFWIRX3HYQ56 Regeneron Pharmaceuticals Inc 75886F107 447297.00000000 NS USD 270695198.46000000 1.402947213865 Long EC CORP US N 1 N N N Ionis Pharmaceuticals Inc 549300SI4ZGLG0BLUZ92 Ionis Pharmaceuticals Inc 462222100 1308767.00000000 NS USD 43896045.18000000 0.227502499620 Long EC CORP US N 1 N N N REVOLUTION Medicines Inc 549300JU3X0LBCQ65892 REVOLUTION Medicines Inc 76155X100 848590.00000000 NS USD 23344710.90000000 0.120989944786 Long EC CORP US N 1 N N N Ginkgo Bioworks Holdings Earn Out Shares $20.00 PP N/A Ginkgo Bioworks Holdings Earn Out Shares $20.00 PP 000000000 212706.00000000 NS USD 1580726.34000000 0.008192519214 Long EC CORP US Y 2 N N N INSITRO SER C CVT PFD PP N/A INSITRO SER C CVT PFD PP 000000000 588382.00000000 NS USD 10762154.00000000 0.055777620199 Long EP CORP US Y 3 N N N Exelixis Inc 254900PJQB59O2O95R37 Exelixis Inc 30161Q104 4276740.00000000 NS USD 90410283.60000000 0.468574456447 Long EC CORP US N 1 N N N Prelude Therapeutics Inc N/A Prelude Therapeutics Inc 74065P101 328791.00000000 NS USD 10274718.75000000 0.053251362142 Long EC CORP US N 1 N N N SomaLogic Inc 549300D3W3Q8CN30YO25 SomaLogic Inc 83444K105 551066.00000000 NS USD 6827707.74000000 0.035386344513 Long EC CORP US N 1 N N N Genmab A/S 529900MTJPDPE4MHJ122 Genmab A/S 000000000 216047.00000000 NS 94395670.78000000 0.489229746501 Long EC CORP DK N 2 N N N Color Genomics Series D-1 CVT Pfd Stock PP N/A Color Genomics Series D-1 CVT Pfd Stock PP 000000000 438696.00000000 NS USD 20087889.84000000 0.104110635296 Long EP CORP US Y 3 N N N Teleflex Inc UUL85LWXB4NGSWWXIQ25 Teleflex Inc 879369106 405745.00000000 NS USD 152783279.75000000 0.791838487974 Long EC CORP US N 1 N N N Merck KGaA 529900OAREIS0MOPTW25 Merck KGaA 000000000 448395.00000000 NS 97050512.75000000 0.502989145139 Long EC CORP DE N 2 N N N AADI BIOSCIENCES INC PP N/A AADI BIOSCIENCES INC PP 000000000 405655.00000000 NS USD 11318382.98000000 0.058660419385 Long EC CORP US Y 2 N N N Mettler-Toledo International I 5493000BD5GJNUDIUG10 Mettler-Toledo International Inc 592688105 45060.00000000 NS USD 62063841.60000000 0.321661758870 Long EC CORP US N 1 N N N Seer Inc N/A Seer Inc 81578P106 2630514.00000000 NS USD 90831648.42000000 0.470758287574 Long EC CORP US N 1 N N N THERMO FISHER SCIENTIFIC INC HCHV7422L5HDJZCRFL38 THERMO FISHER SCIENTIFIC INC 883556102 1422670.00000000 NS USD 812814051.10000000 4.212617049983 Long EC CORP US N 1 N N N Molina Healthcare Inc 549300NQQCEQ46YHZ591 Molina Healthcare Inc 60855R100 665900.00000000 NS USD 180665329.00000000 0.936344351154 Long EC CORP US N 1 N N N PTC Therapeutics Inc 549300UJLWOIWFDGB318 PTC Therapeutics Inc 69366J200 414054.00000000 NS USD 15406949.34000000 0.079850461972 Long EC CORP US N 1 N N N C4 Therapeutics Inc N/A C4 Therapeutics Inc 12529R107 1169227.00000000 NS USD 52241062.36000000 0.270752689018 Long EC CORP US N 1 N N N Series A-4 CVT Pfd N/A Series A-4 CVT Pfd 000000000 593540.00000000 NS USD 1356306.56000000 0.007029406211 Long EP CORP US Y 3 N N N Kronos Bio Inc N/A Kronos Bio Inc 50107A104 552898.00000000 NS USD 11588742.08000000 0.060061624682 Long EC CORP US N 1 N N N Radius Health Inc 549300EV6I2M6E0YVT27 Radius Health Inc 750469207 507175.00000000 NS USD 6294041.75000000 0.032620483803 Long EC CORP US N 1 N N N Ginkgo Bioworks Holdings Earn Out Shares $15.00 PP N/A Ginkgo Bioworks Holdings Earn Out Shares $15.00 PP 000000000 212706.00000000 NS USD 1701031.15000000 0.008816029712 Long EC CORP US Y 2 N N N TEMPUS LAB SERIES E CVT PFD STOCK PP N/A TEMPUS LAB SERIES E CVT PFD STOCK PP 000000000 633505.00000000 NS USD 36165786.84000000 0.187438455403 Long EP CORP US Y 3 N N N Centene Corp 549300Z7JJ4TQSQGT333 Centene Corp 15135B101 4396641.00000000 NS USD 273954700.71000000 1.419840419308 Long EC CORP US N 1 N N N Iovance Biotherapeutics Inc 549300220Z2GHH33XL82 Iovance Biotherapeutics Inc 462260100 1467698.00000000 NS USD 36193432.68000000 0.187581737051 Long EC CORP US N 1 N N N BeiGene Ltd 549300JFUK6FRD5MH739 BeiGene Ltd 07725L102 260250.00000000 NS USD 94470750.00000000 0.489618863793 Long EC CORP CN N 1 N N N Shockwave Medical Inc 549300LDXO56IC5Y1538 Shockwave Medical Inc 82489T104 1000171.00000000 NS USD 205915205.48000000 1.067208304632 Long EC CORP US N 1 N N N SOMALOGIC INC N/A SOMALOGIC INC 000000000 756585.00000000 NS USD 8905383.74000000 0.046154432651 Long EC CORP US Y 2 N N N Elanco Animal Health Inc 549300SHPNDCE059M934 Elanco Animal Health Inc 28414H103 930291.00000000 NS USD 29666979.99000000 0.153756724011 Long EC CORP US N 1 N N N INSCRIPTA SERIES E CVT PFD STOCK PP N/A INSCRIPTA SERIES E CVT PFD STOCK PP 000000000 1452941.00000000 NS USD 12829469.03000000 0.066492009955 Long EP CORP US Y 3 N N N Stryker Corp 5493002F0SC4JTBU5137 Stryker Corp 863667101 1682049.00000000 NS USD 443589962.28000000 2.299018620277 Long EC CORP US N 1 N N N INSITRO SER B CVT PFD PP N/A INSITRO SER B CVT PFD PP 000000000 883580.00000000 NS USD 16161650.14000000 0.083761892210 Long EP CORP US Y 3 N N N Kymera Therapeutics Inc N/A Kymera Therapeutics Inc 501575104 725304.00000000 NS USD 42604356.96000000 0.220807994510 Long EC CORP US N 1 N N N Daiichi Sankyo Co Ltd 353800XGIU2IHQGC9504 Daiichi Sankyo Co Ltd 000000000 1403600.00000000 NS 37309328.90000000 0.193365155086 Long EC CORP JP N 2 N N N Agios Pharmaceuticals Inc 529900ONJHY8EOGYT555 Agios Pharmaceuticals Inc 00847X104 570909.00000000 NS USD 26347450.35000000 0.136552411240 Long EC CORP US N 1 N N N Seagen Inc N/A Seagen Inc 81181C104 998710.00000000 NS USD 169580958.00000000 0.878896758805 Long EC CORP US N 1 N N N PACIFIC BIOSCIENCES OF CALIFORNIA INC N/A PACIFIC BIOSCIENCES OF CALIFORNIA INC 000000000 365964.00000000 NS USD 8882861.19000000 0.046037703766 Long EC CORP US Y 2 N N N Roche Holding AG 549300U41AUUVOAAOB37 Roche Holding AG 000000000 431856.00000000 NS 157614472.86000000 0.816877383942 Long EC CORP CH N 2 N N N Shop Apotheke Europe NV 529900JK6UXHY1YKZ082 Shop Apotheke Europe NV 000000000 68493.00000000 NS 10085863.65000000 0.052272572205 Long EC CORP NL N 2 N N N Bright Health Group, Inc N/A Bright Health Group, Inc 000000000 3127275.00000000 NS USD 24242635.80000000 0.125643670614 Long EC CORP US Y 2 N N N Revolution Healthcare Acquisit N/A Revolution Healthcare Acquisition Corp 76155Y207 1738886.00000000 NS USD 17128027.10000000 0.088770388376 Long EC CORP US N 1 N N N Repligen Corp 54930006QJ0T5AUO1E71 Repligen Corp 759916109 137815.00000000 NS USD 39827156.85000000 0.206414443465 Long EC CORP US N 1 N N N Warby Parker Inc N/A Warby Parker Inc 93403J106 2443421.00000000 NS USD 129623484.05000000 0.671806913584 Long EC CORP US N 1 N N N Vertex Pharmaceuticals Inc 54930015RAQRRZ5ZGJ91 Vertex Pharmaceuticals Inc 92532F100 1558054.00000000 NS USD 282615415.06000000 1.464726790166 Long EC CORP US N 1 N N N Ultragenyx Pharmaceutical Inc 529900EV44GVDN1DCX77 Ultragenyx Pharmaceutical Inc 90400D108 1525947.00000000 NS USD 137625159.93000000 0.713277648735 Long EC CORP US N 1 N N N CLEAR LABS SERIES C CVT PFD PP N/A CLEAR LABS SERIES C CVT PFD PP 000000000 3830773.00000000 NS USD 13293931.54000000 0.068899205901 Long EP CORP US Y 3 N N N Wuxi Biologics Cayman Inc 5493001TD2TH6VDTJU11 Wuxi Biologics Cayman Inc 000000000 2865500.00000000 NS 46479258.19000000 0.240890662823 Long EC CORP CN N 2 N N N AFFINIVAX SERIES C CVT PFD STOCK PP N/A AFFINIVAX SERIES C CVT PFD STOCK PP 000000000 424076.00000000 NS USD 13396306.39000000 0.069429789788 Long EP CORP US Y 3 N N N Helix Acquisition Corp N/A Helix Acquisition Corp 000000000 639149.00000000 NS USD 6308400.63000000 0.032694902377 Long EC CORP US N 1 N N N EXACT SCIENCES EXPENSE FUND PP N/A EXACT SCIENCES EXPENSE FUND PP 000000000 3795.08000000 NS USD 3605.33000000 0.000018685546 Long EC CORP US Y 3 N N N VIVIDION THERAPEUTICS ESCROW PAYMENT N/A VIVIDION THERAPEUTICS ESCROW PAYMENT 000000000 291060.23000000 NS USD 288382.48000000 0.001494616081 Long EC CORP US N 3 N N N IMMUNEERING CORP N/A IMMUNEERING CORP 000000000 974629.00000000 NS USD 24582579.95000000 0.127405518260 Long EC CORP US Y 2 N N N Bio-Techne Corp 54930073RLKQ51TILZ35 Bio-Techne Corp 09073M104 118351.00000000 NS USD 57349344.07000000 0.297227667641 Long EC CORP US N 1 N N N NATIONAL RESILIENCE SER C CVT PFD STOCK N/A NATIONAL RESILIENCE SER C CVT PFD STOCK 000000000 426855.00000000 NS USD 18956630.55000000 0.098247594215 Long EP CORP US Y 3 N N N Blueprint Medicines Corp 5299004CC60O9T5HVM83 Blueprint Medicines Corp 09627Y109 730223.00000000 NS USD 75074226.63000000 0.389091412344 Long EC CORP US N 1 N N N IGM Biosciences Inc 5493008XCQES2N0VY969 IGM Biosciences Inc 449585108 377037.00000000 NS USD 24793953.12000000 0.128501013864 Long EC CORP US N 1 N N N Fate Therapeutics Inc 549300L14Q4UHOODLA90 Fate Therapeutics Inc 31189P102 1206059.00000000 NS USD 71483116.93000000 0.370479566338 Long EC CORP US N 1 N N N LIANBIO SERIES A CVT PFD STOCK PP N/A LIANBIO SERIES A CVT PFD STOCK PP 000000000 202628.00000000 NS USD 11480902.48000000 0.059502718328 Long EP CORP US Y 3 N N N TENAYA THERAPEUTICS INC N/A TENAYA THERAPEUTICS INC 000000000 430747.00000000 NS USD 8450179.27000000 0.043795218869 Long EC CORP US Y 2 N N N Alkermes PLC N/A Alkermes PLC 000000000 76805.00000000 NS USD 2368666.20000000 0.012276219396 Long EC CORP IE N 1 N N N Rocket Pharmaceuticals Inc 549300R7VV82YUIN4Y93 Rocket Pharmaceuticals Inc 77313F106 694370.00000000 NS USD 20754719.30000000 0.107566649804 Long EC CORP US N 1 N N N Turning Point Therapeutics Inc N/A Turning Point Therapeutics Inc 90041T108 531122.00000000 NS USD 35282434.46000000 0.182860255392 Long EC CORP US N 1 N N N 10X Genomics Inc 5493003Z6741WNLG7H43 10X Genomics Inc 88025U109 503125.00000000 NS USD 73244937.50000000 0.379610652793 Long EC CORP US N 1 N N N Veeva Systems Inc 549300YZEXPDB92M2F02 Veeva Systems Inc 922475108 594731.00000000 NS USD 171383632.27000000 0.888239580026 Long EC CORP US N 1 N N N AtriCure Inc N/A AtriCure Inc 04963C209 305070.00000000 NS USD 21217618.50000000 0.109965743495 Long EC CORP US N 1 N N N Alcon Inc 549300LDT5AP8S0NBM78 Alcon Inc 000000000 513245.00000000 NS 41557831.92000000 0.215384110387 Long EC CORP CH N 2 N N N UNITEDHEALTH GROUP INC 549300GHBMY8T5GXDE41 UNITEDHEALTH GROUP INC 91324P102 2901526.00000000 NS USD 1133742269.24000000 5.875909757248 Long EC CORP US N 1 N N N Monte Rosa Therapeutics, Inc. N/A Monte Rosa Therapeutics, Inc. 000000000 679381.00000000 NS USD 14379778.25000000 0.074526884653 Long EC CORP US Y 2 N N N BioNTech SE 894500UZJ5LG1F8J1U58 BioNTech SE 09075V102 888020.00000000 NS USD 242420579.80000000 1.256406759147 Long EC CORP DE N 1 N N N ADC Therapeutics SA N/A ADC Therapeutics SA 000000000 1072666.00000000 NS USD 29133608.56000000 0.150992389933 Long EC CORP CH N 1 N N N Cortexyme Inc N/A Cortexyme Inc 22053A107 65500.00000000 NS USD 6003730.00000000 0.031115868786 Long EC CORP US N 1 N N N FOG PHARMACEUTICALS SERIES C CVT PFD STOCK PP N/A FOG PHARMACEUTICALS SERIES C CVT PFD STOCK PP 000000000 431391.00000000 NS USD 6250596.76000000 0.032395319013 Long EP CORP US Y 3 N N N Quantum-Si Inc N/A Quantum-Si Inc 74765K105 1866008.00000000 NS USD 15562506.72000000 0.080656677945 Long EC CORP US N 1 N N N Biopharmaceuticals, Inc N/A Biopharmaceuticals, Inc 000000000 270332.00000000 NS USD 6094229.44000000 0.031584905318 Long EC CORP US Y 2 N N N Multiplan Corp N/A Multiplan Corp 62548M100 1988518.00000000 NS USD 11195356.34000000 0.058022802306 Long EC CORP US N 1 N N N Inari Medical Inc N/A Inari Medical Inc 45332Y109 167497.00000000 NS USD 13584006.70000000 0.070402594731 Long EC CORP US N 1 N N N Pennant Group Inc/The 5493007H2OYR6BYLDA64 Pennant Group Inc/The 70805E109 504314.00000000 NS USD 14166180.26000000 0.073419858349 Long EC CORP US N 1 N N N SPAC FSII/ PARDES BIO PIPE COMMIT PP N/A SPAC FSII/ PARDES BIO PIPE COMMIT PP 000000000 530954.00000000 NS USD 4754693.07000000 0.024642414912 Long EC CORP US N 2 N N N Adaptive Biotechnologies Corp 549300ZTF7OT1FW66Q96 Adaptive Biotechnologies Corp 00650F109 1255261.00000000 NS USD 42666321.39000000 0.221129141043 Long EC CORP US N 1 N N N Certara Inc N/A Certara Inc 15687V109 896790.00000000 NS USD 29683749.00000000 0.153843633701 Long EC CORP US N 1 N N N ZENECA INC N/A ZENECA (OMTHERA) CVR PP 000000000 375635.00000000 NS USD 0.00000000 0.000000 Long EC CORP US Y 3 N N N Nurix Therapeutics Inc N/A Nurix Therapeutics Inc 67080M103 710773.00000000 NS USD 21294759.08000000 0.110365544313 Long EC CORP US N 1 N N N PRIME MEDICINE SER B CVT PFD STOCK PP N/A PRIME MEDICINE SER B CVT PFD STOCK PP 000000000 1625121.00000000 NS USD 7118517.52000000 0.036893540699 Long EP CORP US Y 3 N N N ACADIA Pharmaceuticals Inc 529900O3044NO0PEA039 ACADIA Pharmaceuticals Inc 004225108 1096469.00000000 NS USD 18212350.09000000 0.094390170058 Long EC CORP US N 1 N N N SOMALOGIC INC EARN OUT SHS $20 PP N/A SOMALOGIC INC EARN OUT SHS $20 PP 000000000 3873442.00000000 NS USD 321450.06000000 0.001665997286 Long EC CORP US Y 2 N N N DANAHER CORP S4BKK9OTCEWQ3YHPFM11 DANAHER CORP 235851102 2423520.00000000 NS USD 737816428.80000000 3.823922659204 Long EC CORP US N 1 N N N Deciphera Pharmaceuticals Inc 529900QR4WAPYY0CBF25 Deciphera Pharmaceuticals Inc 24344T101 96883.00000000 NS USD 3292084.34000000 0.017062070472 Long EC CORP US N 1 N N N MeiraGTx Holdings plc 54930007YV6NYIOGFZ57 MeiraGTx Holdings plc 000000000 494331.00000000 NS USD 6515282.58000000 0.033767121083 Long EC CORP US N 1 N N N ALNYLAM PHARMACEUTICALS INC 529900S3ZI14OWRJII50 ALNYLAM PHARMACEUTICALS INC 02043Q107 1202350.00000000 NS USD 227015703.50000000 1.176567041236 Long EC CORP US N 1 N N N Outset Medical Inc N/A Outset Medical Inc 690145107 641577.00000000 NS USD 31719566.88000000 0.164394781409 Long EC CORP US N 1 N N N Amgen Inc 62QBXGPJ34PQ72Z12S66 Amgen Inc 031162100 634354.00000000 NS USD 134895378.10000000 0.699129855074 Long EC CORP US N 1 N N N Sophia Genetics SA N/A Sophia Genetics SA 000000000 1146130.00000000 NS USD 20091658.90000000 0.104130169415 Long EC CORP CH N 1 N N N Royalty Pharma PLC 549300FGFN7VOK8BZR03 Royalty Pharma PLC 000000000 1597128.00000000 NS USD 57720205.92000000 0.299149754188 Long EC CORP US N 1 N N N NATIONAL RESILIENCE SER B CVT PFD STOCK N/A NATIONAL RESILIENCE SER B CVT PFD STOCK 000000000 1204832.00000000 NS USD 53506589.12000000 0.277311605659 Long EP CORP US Y 3 N N N VERILY LIFE SCIENCES LLC SER B UNITS PP N/A VERILY LIFE SCIENCES LLC SER B UNITS PP 000000000 113564.00000000 NS USD 14845086.08000000 0.076938461686 Long EC CORP US Y 3 N N N SEMA4 HOLDINGS CORP N/A CM LIFE SCIENCES INC-A -CW27 81663L119 253101.00000000 NS USD 536574.12000000 0.002780932838 Long EC CORP US N 1 N N N Argenx SE 7245009C5FZE6G9ODQ71 Argenx SE 04016X101 824888.00000000 NS USD 249116176.00000000 1.291108401760 Long EC CORP NL N 1 N N N Catalent Inc N/A Catalent Inc 148806102 804457.00000000 NS USD 107049092.99000000 0.554809348712 Long EC CORP US N 1 N N N Imago Biosciences Inc N/A Imago Biosciences Inc 45250K107 240093.00000000 NS USD 4809062.79000000 0.024924199915 Long EC CORP US N 1 N N N GYROSCOPE THERA SR C-1 CVT PFD N/A GYROSCOPE THERA SR C-1 CVT PFD 000000000 3555744.00000000 NS USD 8178211.20000000 0.042385674672 Long EP CORP US Y 3 N N N Olink Holding AB 8945004Z7ZHV3LML4J27 Olink Holding AB 680710100 1692804.00000000 NS USD 41050497.00000000 0.212754717193 Long EC CORP SE N 1 N N N MaxCyte Inc 54930053YHXULRFCU991 MaxCyte Inc 57777K106 422700.00000000 NS USD 5161167.00000000 0.026749070187 Long EC CORP US N 1 N N N Immuneering Corp N/A Immuneering Corp 45254E107 401531.00000000 NS USD 10660648.05000000 0.055251539609 Long EC CORP US N 1 N N N Doximity Inc N/A Doximity Inc 26622P107 574338.00000000 NS USD 46349076.60000000 0.240215963382 Long EC CORP US N 1 N N N TEMPUS LABS SERIES G-2 CVT PFD STOCK PP N/A TEMPUS LABS SERIES G-2 CVT PFD STOCK PP 000000000 117271.00000000 NS USD 6720437.47000000 0.034830388858 Long EP CORP US Y 3 N N N REFLEXION MEDICAL INC CVT N/A REFLEXION MEDICAL INC CVT 000000000 1123437.00000000 NS USD 2561284.70000000 0.013274514118 Long EP CORP US Y 3 N N N Invitae Corp 549300MYI59DZW1WIX92 Invitae Corp 46185L103 901387.00000000 NS USD 25626432.41000000 0.132815551053 Long EC CORP US N 1 N N N Avantor Inc N/A Avantor Inc 05352A100 4373940.00000000 NS USD 178894146.00000000 0.927164741507 Long EC CORP US N 1 N N N Dicerna Pharmaceuticals Inc 549300CTZMJMPH28WN39 Dicerna Pharmaceuticals Inc 253031108 868406.00000000 NS USD 17507064.96000000 0.090734849189 Long EC CORP US N 1 N N N Zymeworks Inc 894500AHOYAGYLYZJL67 Zymeworks Inc 98985W102 490021.00000000 NS USD 14230209.84000000 0.073751708051 Long EC CORP CA N 1 N N N Day One Biopharmaceuticals Inc N/A Day One Biopharmaceuticals Inc 23954D109 200661.00000000 NS USD 4761685.53000000 0.024678655128 Long EC CORP US N 1 N N N Intellia Therapeutics Inc 5493002T5BCPE5DZC723 Intellia Therapeutics Inc 45826J105 475904.00000000 NS USD 63842521.60000000 0.330880223640 Long EC CORP US N 1 N N N Rapid Micro Biosystems Inc N/A Rapid Micro Biosystems Inc 75340L104 336580.00000000 NS USD 6216632.60000000 0.032219291052 Long EC CORP US N 1 N N N Centessa Pharmaceuticals N/A Centessa Pharmaceuticals 000000000 649336.00000000 NS USD 10301715.64000000 0.053391280441 Long EC CORP US Y 2 N N N Guardant Health Inc 254900M8C3E5VC8BR186 Guardant Health Inc 40131M109 872150.00000000 NS USD 109027471.50000000 0.565062802169 Long EC CORP US N 1 N N N ICU Medical Inc 5493003NRW7LS2QZRH60 ICU Medical Inc 44930G107 7833.00000000 NS USD 1828065.54000000 0.009474417982 Long EC CORP US N 1 N N N Sema4 Holdings Corp N/A Sema4 Holdings Corp 81663L101 1419923.00000000 NS USD 10777215.57000000 0.055855680644 Long EC CORP US N 1 N N N TEMPUS LABS SERIES F CVT PFD STOCK PP N/A TEMPUS LABS SERIES F CVT PFD STOCK PP 000000000 172826.00000000 NS USD 9948227.49000000 0.051559237546 Long EP CORP US Y 3 N N N CRISPR Therapeutics AG 506700O6IRRIQLT3W370 CRISPR Therapeutics AG 000000000 251390.00000000 NS USD 28138082.70000000 0.145832822126 Long EC CORP CH N 1 N N N Mersana Therapeutics Inc 529900VWD5VDZ7PVOS22 Mersana Therapeutics Inc 59045L106 241556.00000000 NS USD 2277873.08000000 0.011805660792 Long EC CORP US N 1 N N N Immunocore Holdings PLC 213800IUE3DFS84BVN18 Immunocore Holdings PLC 45258D105 304616.00000000 NS USD 11292115.12000000 0.058524279471 Long EC CORP GB N 1 N N N Twist Bioscience Corp 549300T23BL59LCOH584 Twist Bioscience Corp 90184D100 398661.00000000 NS USD 42644767.17000000 0.221017430776 Long EC CORP US N 1 N N N Schrodinger Inc/United States N/A Schrodinger Inc/United States 80810D103 207182.00000000 NS USD 11328711.76000000 0.058713950933 Long EC CORP US N 1 N N N - EXACT SCIENCES CMO MILESTONE PP N/A - EXACT SCIENCES CMO MILESTONE PP 000000000 3726271.69000000 NS USD 2981017.35000000 0.015449886106 Long EC CORP US Y 3 N N N Annexon Inc N/A Annexon Inc 03589W102 571522.00000000 NS USD 10636024.42000000 0.055123921338 Long EC CORP US N 1 N N N EXACT SCIENCES CORP 549300VM3X1FYD4N9Z14 EXACT SCIENCES CORP 30063P105 1341605.00000000 NS USD 128056197.25000000 0.663684048228 Long EC CORP US N 1 N N N Reata Pharmaceuticals Inc 5299005F094GH9QDDD80 Reata Pharmaceuticals Inc 75615P103 186798.00000000 NS USD 18793746.78000000 0.097403407349 Long EC CORP US N 1 N N N Global Blood Therapeutics Inc 549300U4G0QKK99GRT15 Global Blood Therapeutics Inc 37890U108 159954.00000000 NS USD 4075627.92000000 0.021122985807 Long EC CORP US N 1 N N N BIOGEN INC W8J5WZB5IY3K0NDQT671 BIOGEN INC 09062X103 526309.00000000 NS USD 148940183.91000000 0.771920659242 Long EC CORP US N 1 N N N West Pharmaceutical Services I 5493007NKRGM1RJQ1P16 West Pharmaceutical Services Inc 955306105 652954.00000000 NS USD 277205091.16000000 1.436686400514 Long EC CORP US N 1 N N N Mirati Therapeutics Inc 529900GYRW59IDQV6N54 Mirati Therapeutics Inc 60468T105 702359.00000000 NS USD 124254330.69000000 0.643979900803 Long EC CORP US N 1 N N N ANTHEM INC 8MYN82XMYQH89CTMTH67 ANTHEM INC 036752103 811789.00000000 NS USD 302634939.20000000 1.568483102708 Long EC CORP US N 1 N N N PMV Pharmaceuticals Inc N/A PMV Pharmaceuticals Inc 69353Y103 96760.00000000 NS USD 2883448.00000000 0.014944207953 Long EC CORP US N 1 N N N Zentalis Pharmaceuticals Inc N/A Zentalis Pharmaceuticals Inc 98943L107 915673.00000000 NS USD 61020448.72000000 0.316254107969 Long EC CORP US N 1 N N N LUMICKS TECH SER D CVT PFD STOCK PP N/A LUMICKS TECH SER D CVT PFD STOCK PP 000000000 4954.00000000 NS USD 8875383.29000000 0.045998947633 Long EP CORP US Y 3 N N N Cara Therapeutics Inc 549300COVOY41P0GZ881 Cara Therapeutics Inc 140755109 383715.00000000 NS USD 5928396.75000000 0.030725434918 Long EC CORP US N 1 N N N Atea Pharmaceuticals Inc N/A Atea Pharmaceuticals Inc 04683R106 877193.00000000 NS USD 30754386.58000000 0.159392487240 Long EC CORP US N 1 N N N HCA HEALTHCARE INC 529900PH4ZGUH2MNEU89 HCA HEALTHCARE INC 40412C101 1150869.00000000 NS USD 279338923.68000000 1.447745534204 Long EC CORP US N 1 N N N SCRIBE THERA SER B CVT PFD STOCK PP N/A SCRIBE THERA SER B CVT PFD STOCK PP 000000000 1027755.00000000 NS USD 6219253.83000000 0.032232876248 Long EP CORP US Y 3 N N N SOMALOGIC INC 549300D3W3Q8CN30YO25 CM LIFE SCIENCES II -CW27 83444K113 110601.00000000 NS USD 381573.45000000 0.001977602157 Long EC CORP US N 1 N N N Hologic Inc 549300DYP6F5ZJL0LB74 Hologic Inc 436440101 2907559.00000000 NS USD 214606929.79000000 1.112255392551 Long EC CORP US N 1 N N N RING THERA SER B CVT PFD STOCK PP N/A RING THERA SER B CVT PFD STOCK PP 000000000 978705.00000000 NS USD 9004086.00000000 0.046665982400 Long EP CORP US Y 3 N N N iRhythm Technologies Inc 549300FJI72RJGDQS384 iRhythm Technologies Inc 450056106 284041.00000000 NS USD 16633440.96000000 0.086207069000 Long EC CORP US N 1 N N N Sage Therapeutics Inc 5493000JX4BJS9W6CN35 Sage Therapeutics Inc 78667J108 433051.00000000 NS USD 19188489.81000000 0.099449264229 Long EC CORP US N 1 N N N AstraZeneca PLC PY6ZZQWO2IZFZC3IOL08 AstraZeneca PLC 046353108 6584457.00000000 NS USD 395462487.42000000 2.049585652314 Long EC CORP GB N 1 N N N CARIS LIFE SCIENCES SER C CVT PFD PP N/A CARIS LIFE SCIENCES SER C CVT PFD PP 000000000 3758668.00000000 NS USD 30445210.80000000 0.157790104554 Long EP CORP US Y 3 N N N KARDIUM SERIES D6 CVT PFD STOCK PP N/A KARDIUM SERIES D6 CVT PFD STOCK PP 000000000 12320393.00000000 NS USD 12515548.03000000 0.064865033951 Long EP CORP US Y 3 N N N Tenaya Therapeutics Inc N/A Tenaya Therapeutics Inc 87990A106 296851.00000000 NS USD 6129973.15000000 0.031770156252 Long EC CORP US N 1 N N N 2021-11-23 T. ROWE PRICE HEALTH SCIENCES FUND, INC. Alan S. Dupski Alan S. Dupski Treasurer & Vice President XXXX NPORT-EX 2 70F1TRP093021.htm
T.
ROWE
PRICE
Health
Sciences
Fund
September
30,
2021
(Unaudited)
1
Portfolio
of
Investments
Shares
$
Value
(Cost
and
value
in
$000s)
COMMON
STOCKS
96.4%
BIOTECHNOLOGY
29.3%
Major
Biotechnology
6.3%
Alkermes (1)
76,805‌
2,369‌
Amgen 
634,354‌
134,895‌
Biogen (1)
526,309‌
148,940‌
BioNTech,
ADR (1)
888,020‌
242,421‌
Exact
Sciences (1)
1,328,703‌
126,825‌
Exact
Sciences
CMO
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
3,726,272‌
2,981‌
Exact
Sciences
Expense
Fund,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
3,795‌
4‌
Exact
Sciences
FDA
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
1,863,136‌
1,490‌
Neurocrine
Biosciences (1)
365,109‌
35,018‌
Novavax (1)
291,207‌
60,370‌
Seagen (1)
998,710‌
169,581‌
Vertex
Pharmaceuticals (1)
1,558,054‌
282,615‌
1,207,509‌
Other
Biotechnology
23.0%
AADI
Biosciences,
Acquisition
Date:
8/27/21,
Cost $5,305 (1)(3)
405,655‌
11,318‌
AC
Immune (1)
335,619‌
2,252‌
ACADIA
Pharmaceuticals (1)
1,096,469‌
18,212‌
Acceleron
Pharma (1)
1,526,603‌
262,728‌
Acerta
Future
Payments,
EC,
Acquisition
Date:
6/30/21,
Cost $25,373 (1)(2)(3)
25,372,879‌
22,772‌
Adaptive
Biotechnologies (1)
1,255,261‌
42,666‌
ADC
Therapeutics (1)
1,072,666‌
29,134‌
Agios
Pharmaceuticals (1)
570,909‌
26,347‌
Akero
Therapeutics (1)
320,250‌
7,158‌
Alector (1)
513,521‌
11,719‌
Allogene
Therapeutics (1)
1,265,834‌
32,532‌
Alnylam
Pharmaceuticals (1)
1,202,350‌
227,016‌
Annexon (1)
584,685‌
10,881‌
Apellis
Pharmaceuticals (1)
1,237,214‌
40,779‌
Arvinas (1)
549,763‌
45,180‌
Ascendis
Pharma,
ADR (1)
813,997‌
129,743‌
Atea
Pharmaceuticals (1)
933,093‌
32,714‌
Avidity
Biosciences (1)
963,638‌
23,734‌
BeiGene,
ADR (1)
260,250‌
94,471‌
Blueprint
Medicines (1)
730,223‌
75,074‌
C4
Therapeutics (1)
1,169,227‌
52,241‌
Centessa
Pharmaceuticals,
Acquisition
Date:
1/29/21,
Cost $7,143 (1)(3)
649,336‌
10,302‌
T.
ROWE
PRICE
Health
Sciences
Fund
2
Shares
$
Value
(Cost
and
value
in
$000s)
Cerevel
Therapeutics
Holdings (1)
1,769,216‌
52,192‌
CM
Life
Sciences
III
SPAC/EQRX
PIPE (1)(4)
884,467‌
7,896‌
Cortexyme (1)
65,500‌
6,004‌
CRISPR
Therapeutics (1)
251,390‌
28,138‌
CureVac (1)
405,872‌
22,169‌
Day
One
Biopharmaceuticals (1)
200,661‌
4,762‌
Day
One
Biopharmaceuticals,
Acquisition
Date:
2/2/21,
Cost $3,646 (1)(3)
270,332‌
6,094‌
Deciphera
Pharmaceuticals (1)
96,883‌
3,292‌
Denali
Therapeutics (1)
1,432,855‌
72,288‌
DICE
Therapeutics (1)
474,448‌
15,538‌
Dicerna
Pharmaceuticals (1)
868,406‌
17,507‌
Enanta
Pharmaceuticals (1)
220,225‌
12,511‌
Evotec
(EUR) (1)
887,021‌
42,060‌
Exelixis (1)
4,276,740‌
90,410‌
Fate
Therapeutics (1)
1,206,059‌
71,483‌
Flame
Biosciences,
Acquisition
Date:
9/28/20,
Cost $5,500 (1)(2)
(3)
839,721‌
5,500‌
Generation
Bio (1)
1,736,219‌
43,527‌
Genmab
(DKK) (1)
215,537‌
94,173‌
Genmab,
ADR (1)
45,647‌
1,995‌
Ginkgo
Bioworks,
Acquisition
Date:
5/11/21,
Cost $5,479 (1)(3)
547,946‌
6,033‌
Ginkgo
Bioworks,
Acquisition
Date:
6/30/19-9/9/19,
Cost $21,415 (1)(3)
7,090,407‌
78,069‌
Ginkgo
Bioworks,
Earn
Out
Shares
$12.50,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,707‌
1,770‌
Ginkgo
Bioworks,
Earn
Out
Shares
$15.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706‌
1,701‌
Ginkgo
Bioworks,
Earn
Out
Shares
$17.50,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706‌
1,638‌
Ginkgo
Bioworks,
Earn
Out
Shares
$20.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706‌
1,581‌
Global
Blood
Therapeutics (1)
159,954‌
4,076‌
IGM
Biosciences (1)
377,037‌
24,794‌
Imago
Biosciences (1)
240,093‌
4,809‌
Imago
Biosciences,
Acquisition
Date:
11/12/20,
Cost $5,370 (1)(3)
529,300‌
10,072‌
Immuneering (1)(5)
401,531‌
10,661‌
Immuneering,
Series
B,
Acquisition
Date:
12/21/20-5/4/21,
Cost $7,155 (1)(3)(5)
974,629‌
24,583‌
Immunocore
Holdings,
ADR (1)
304,616‌
11,292‌
Incyte (1)
2,310,007‌
158,882‌
Insmed (1)
2,316,374‌
63,793‌
Intellia
Therapeutics (1)
475,904‌
63,843‌
Ionis
Pharmaceuticals (1)
1,308,767‌
43,896‌
Iovance
Biotherapeutics (1)
1,467,698‌
36,193‌
IVERIC
bio (1)
2,537,772‌
41,213‌
T.
ROWE
PRICE
Health
Sciences
Fund
3
Shares
$
Value
(Cost
and
value
in
$000s)
Karuna
Therapeutics (1)
427,366‌
52,280‌
Kodiak
Sciences (1)
1,364,585‌
130,973‌
Kronos
Bio (1)
552,898‌
11,589‌
Kymera
Therapeutics (1)
758,404‌
44,549‌
Longboard
Pharmaceuticals (1)(5)
780,435‌
6,954‌
Lonza
Group
(CHF) 
77,625‌
58,227‌
MeiraGTx
Holdings (1)
494,331‌
6,515‌
Mersana
Therapeutics (1)
241,556‌
2,278‌
Mirati
Therapeutics (1)
702,359‌
124,254‌
Moderna (1)
1,276,162‌
491,144‌
Monte
Rosa
Therapeutics (1)
393,209‌
8,761‌
Monte
Rosa
Therapeutics,
Inc.,
Acquisition
Date:
3/11/21,
Cost $7,109 (1)(3)
679,381‌
14,380‌
Novocure (1)
563,219‌
65,429‌
Nurix
Therapeutics (1)
729,228‌
21,848‌
Prelude
Therapeutics (1)
328,791‌
10,275‌
Progenic
Pharmaceuticals,
CVR 
842,223‌
41‌
Protagonist
Therapeutics (1)
388,176‌
6,878‌
Prothena (1)
1,006,244‌
71,675‌
PTC
Therapeutics (1)
414,054‌
15,407‌
Radius
Health (1)
507,175‌
6,294‌
RAPT
Therapeutics (1)
738,777‌
22,939‌
Reata
Pharmaceuticals,
Class
A (1)
186,798‌
18,794‌
Regeneron
Pharmaceuticals (1)
447,297‌
270,695‌
REGENXBIO (1)
238,760‌
10,009‌
Relay
Therapeutics (1)
370,846‌
11,693‌
Repligen (1)
137,815‌
39,827‌
Replimune
Group (1)
1,248,619‌
37,009‌
REVOLUTION
Medicines (1)
848,590‌
23,345‌
Rocket
Pharmaceuticals (1)
694,370‌
20,755‌
Sage
Therapeutics (1)
433,051‌
19,188‌
Sarepta
Therapeutics (1)
279,992‌
25,894‌
Scholar
Rock
Holding (1)
952,830‌
31,462‌
Seres
Therapeutics (1)
471,039‌
3,278‌
Stoke
Therapeutics (1)
254,758‌
6,481‌
Tenaya
Therapeutics (1)
296,851‌
6,130‌
Tenaya
Therapeutics,
Acquisition
Date:
12/17/20,
Cost $5,355 (1)
(3)
430,747‌
8,450‌
Turning
Point
Therapeutics (1)
531,122‌
35,282‌
Ultragenyx
Pharmaceutical (1)
1,525,947‌
137,625‌
uniQure (1)
416,122‌
13,320‌
Vividion
Therapeutics,
EC,
Acquisition
Date:
8/25/21,
Cost $—  (1)
(2)
291,060‌
288‌
Vividion
Therapeutics,
Milestone
Payment,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
2,328,482‌
1,138‌
T.
ROWE
PRICE
Health
Sciences
Fund
4
Shares
$
Value
(Cost
and
value
in
$000s)
Vividion
Therapeutics,
Milestone
Payment,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
1,746,361‌
1,024‌
Vividion
Therapeutics,
Milestone
Payment
3,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
1,746,361‌
711‌
Xencor (1)
988,502‌
32,284‌
Zai
Lab,
ADR (1)
436,922‌
46,047‌
Zentalis
Pharmaceuticals (1)
915,673‌
61,020‌
Zymeworks (1)
490,021‌
14,230‌
4,444,080‌
Total
Biotechnology
5,651,589‌
CONSUMER
NONDURABLES
0.2%
Hospital
Supplies/Hosp
Management
0.2%
PROCEPT
BioRobotics (1)
268,312‌
10,236‌
PROCEPT
BioRobotics,
Acquisition
Date:
6/10/21,
Cost $13,279 (1)(3)
694,834‌
25,183‌
Total
Consumer
Nondurables
35,419‌
LIFE
SCIENCES
14.3%
Life
Sciences
14.3%
Abcam
(GBP) (1)
1,471,081‌
29,485‌
Agilent
Technologies 
2,218,531‌
349,485‌
Berkeley
Lights (1)
331,312‌
6,481‌
Bio-Techne 
118,351‌
57,349‌
Bruker 
2,029,650‌
158,516‌
Danaher 
2,423,520‌
737,816‌
Invitae (1)
901,387‌
25,626‌
MaxCyte (1)
422,700‌
5,161‌
Mettler-Toledo
International (1)
45,060‌
62,064‌
Olink
Holding,
ADR (1)
1,693,859‌
41,076‌
Ortho
Clinical
Diagnostics
Holdings (1)
3,577,780‌
66,117‌
Pacific
Biosciences
of
California (1)
2,701,237‌
69,017‌
Pacific
Biosciences
of
California,
Acquisition
Date:
7/21/21,
Cost $9,789 (1)(3)
365,964‌
8,883‌
Quanterix (1)
596,234‌
29,687‌
Quantum-Si (1)
1,866,008‌
15,563‌
Quidel (1)
436,942‌
61,674‌
Rapid
Micro
Biosystems,
Acquisition
Date:
3/9/21,
Cost $6,665 (1)
(3)
370,289‌
6,497‌
Rapid
Micro
Biosystems,
Class
A (1)
336,580‌
6,217‌
Schrodinger (1)
207,182‌
11,329‌
Seer (1)
2,630,514‌
90,832‌
SomaLogic (1)
551,066‌
6,828‌
SomaLogic,
Acquisition
Date:
11/20/20-9/15/21,
Cost $15,668 (1)
(3)
3,873,442‌
45,592‌
SomaLogic,
Acquisition
Date:
3/29/21,
Cost $7,566 (1)(3)
756,585‌
8,905‌
T.
ROWE
PRICE
Health
Sciences
Fund
5
Shares
$
Value
(Cost
and
value
in
$000s)
SomaLogic,
Warrants,
2/3/21 (1)
110,601‌
382‌
SomaLogic,
Earn
Out
Shares
$20,
Acquisition
Date:
9/2/21,
Cost $— (1)(3)
3,873,442‌
321‌
Thermo
Fisher
Scientific 
1,422,670‌
812,814‌
Twist
Bioscience (1)
398,661‌
42,645‌
Total
Life
Sciences
2,756,362‌
MISCELLANEOUS
0.4%
Miscellaneous
0.4%
Health
Sciences
Acquisitions
Corp
2 (1)
688,861‌
6,813‌
Helix
Acquisition,
Class
A (1)(5)
639,149‌
6,308‌
Revolution
Healthcare
Acquisition (1)
1,738,886‌
17,128‌
Royalty
Pharma,
Class
1,597,128‌
57,720‌
Total
Miscellaneous
87,969‌
PHARMACEUTICALS
9.6%
European
Major
-
Pharmaceuticals
0.5%
Merck
(EUR) 
447,337‌
96,821‌
Zeneca,
CVR,
Acquisition
Date:
7/18/13,
Cost $0 (1)(2)(3)
375,635‌
—‌
96,821‌
Major
Pharmaceuticals
9.1%
AbbVie 
2,638,952‌
284,664‌
AstraZeneca,
ADR 
6,584,457‌
395,462‌
Daiichi
Sankyo
(JPY) 
1,400,200‌
37,219‌
Eisai
(JPY) 
344,900‌
25,836‌
Eli
Lilly 
2,243,718‌
518,411‌
Merck 
4,520,546‌
339,538‌
PMV
Pharmaceuticals (1)
96,760‌
2,883‌
Roche
Holding
(CHF) 
430,837‌
157,243‌
1,761,256‌
Specialty
Pharmaceuticals
0.0%
Cara
Therapeutics (1)
383,715‌
5,928‌
5,928‌
Total
Pharmaceuticals
1,864,005‌
PRODUCTS
&
DEVICES
18.1%
Implants
8.8%
AtriCure (1)
305,070‌
21,218‌
Becton
Dickinson
&
Company 
980,714‌
241,079‌
Intuitive
Surgical (1)
738,824‌
734,502‌
iRhythm
Technologies (1)
284,041‌
16,633‌
Stryker 
1,682,049‌
443,590‌
Teleflex 
405,745‌
152,783‌
Verily
Life
Sciences,
Series
B,
Acquisition
Date:
1/23/19,
Cost $13,998 (1)(2)(3)
113,564‌
14,845‌
T.
ROWE
PRICE
Health
Sciences
Fund
6
Shares
$
Value
(Cost
and
value
in
$000s)
Zimmer
Biomet
Holdings 
444,930‌
65,120‌
1,689,770‌
Other
Products
&
Devices
9.3%
10X
Genomics,
Class
A (1)
503,125‌
73,245‌
Alcon
(CHF) 
512,034‌
41,460‌
Argenx,
ADR (1)
824,888‌
249,116‌
Avantor (1)
4,373,940‌
178,894‌
Burning
Rock
Biotech,
ADR (1)
456,624‌
8,164‌
Catalent (1)
804,457‌
107,049‌
Cooper 
197,335‌
81,561‌
Dexcom (1)
284,357‌
155,503‌
Hologic (1)
2,907,559‌
214,607‌
ICU
Medical (1)
7,833‌
1,828‌
Inari
Medical (1)
167,497‌
13,584‌
Insulet (1)
313,825‌
89,199‌
Lantheus
Holdings (1)
878,190‌
22,552‌
Nevro (1)
245,132‌
28,528‌
Outset
Medical (1)
641,577‌
31,720‌
Pax
Labs,
Class
A,
Acquisition
Date:
4/18/19,
Cost $31,622 (1)(2)
(3)
8,397,988‌
10,665‌
Penumbra (1)
546,904‌
145,750‌
Shockwave
Medical (1)
1,000,171‌
205,915‌
Warby
Parker,
Class
A (1)
2,443,421‌
129,624‌
1,788,964‌
Total
Products
&
Devices
3,478,734‌
SERVICES
20.5%
Distribution
0.3%
Option
Care
Health (1)
1,666,189‌
40,422‌
Shop
Apotheke
Europe
(EUR) (1)
68,332‌
10,062‌
50,484‌
Information
0.3%
Definitive
Healthcare (1)
615,230‌
26,350‌
Sema4
Holdings (1)
1,419,923‌
10,777‌
Sema4
Holdings,
Warrants,
10/23/20 (1)
253,101‌
537‌
Sophia
Genetics (1)
1,146,130‌
20,092‌
57,756‌
Information
1.9%
Doximity,
Class
A (1)(5)
574,338‌
46,349‌
Doximity,
Series
C,
Acquisition
Date:
4/10/14,
Cost $4,993 (1)(3)
(5)
2,071,266‌
158,793‌
Veeva
Systems,
Class
A (1)
594,731‌
171,384‌
376,526‌
T.
ROWE
PRICE
Health
Sciences
Fund
7
Shares
$
Value
(Cost
and
value
in
$000s)
Other
Services
3.3%
Accolade (1)
444,589‌
18,748‌
Agiliti (1)
1,604,221‌
30,544‌
Certara (1)
896,790‌
29,684‌
Elanco
Animal
Health (1)
930,291‌
29,667‌
Guardant
Health (1)
872,150‌
109,028‌
Multiplan (1)
1,988,518‌
11,195‌
Pennant
Group (1)
504,314‌
14,166‌
Phreesia (1)
1,174,872‌
72,490‌
West
Pharmaceutical
Services 
652,954‌
277,205‌
Wuxi
Biologics
Cayman
(HKD) (1)
2,858,500‌
46,366‌
639,093‌
Payors
12.8%
Alignment
Healthcare (1)
2,570,009‌
41,069‌
Anthem 
811,789‌
302,635‌
Bright
Health
Group,
Acquisition
Date:
9/16/20,
Cost $21,284 (1)
(3)
3,127,275‌
24,243‌
Centene (1)
4,396,641‌
273,955‌
Cigna 
918,399‌
183,827‌
Humana 
823,804‌
320,583‌
Molina
Healthcare (1)
665,900‌
180,665‌
UnitedHealth
Group 
2,901,526‌
1,133,742‌
2,460,719‌
Providers
1.9%
agilon
health (1)
936,437‌
24,544‌
FS
Development
SPAC/Pardes
Bio
PIPE (1)(4)
530,954‌
4,755‌
HCA
Healthcare 
1,150,869‌
279,339‌
Oak
Street
Health (1)
465,354‌
19,791‌
Surgery
Partners (1)
823,568‌
34,870‌
363,299‌
Total
Services
3,947,877‌
Total
Miscellaneous
Common
Stocks
 4.0% (6)
776,610‌
Total
Common
Stocks
(Cost
$8,717,035)
18,598,565‌
CONVERTIBLE
PREFERRED
STOCKS
3.0%
BIOTECHNOLOGY
0.9%
Other
Biotechnology
0.9%
Affinivax,
Series
C,
Acquisition
Date:
1/6/21,
Cost $13,396 (1)(2)
(3)
424,076‌
13,396‌
Delfi
Diagnostics,
Series
A,
Acquisition
Date:
1/12/21,
Cost $4,465 (1)(2)(3)
2,152,801‌
4,465‌
T.
ROWE
PRICE
Health
Sciences
Fund
8
Shares
$
Value
(Cost
and
value
in
$000s)
FOG
Pharma,
Series
C,
Acquisition
Date:
1/11/21-8/2/21,
Cost $6,251 (1)(2)(3)
431,391‌
6,251‌
Generate
Bio,
Series
B,
Acquisition
Date:
9/2/21,
Cost $22,096 (1)
(2)(3)
1,864,632‌
22,096‌
Genesis
Therapeutics,
Series
A,
Acquisition
Date:
11/24/20,
Cost $4,236 (1)(2)(3)
829,412‌
4,236‌
Gyroscope
Therapeutics,
Series
C-1,
Acquisition
Date:
3/30/21,
Cost $8,178 (1)(2)(3)
3,555,744‌
8,178‌
Insitro,
Series
B,
Acquisition
Date:
5/21/20,
Cost $5,505 (1)(2)(3)
883,580‌
16,161‌
Insitro,
Series
C,
Acquisition
Date:
4/7/21,
Cost $10,762 (1)(2)(3)
588,382‌
10,762‌
Laronde,
Series
B,
Acquisition
Date:
7/28/21,
Cost $32,757 (1)(2)
(3)
1,169,887‌
32,757‌
Lianbio,
Series
A,
Acquisition
Date:
10/28/20,
Cost $11,481 (1)(2)
(3)
202,628‌
11,481‌
Nutcracker
Therapeutics,
Series
C,
Acquisition
Date:
8/27/21,
Cost $11,050 (1)(2)(3)
1,027,785‌
11,050‌
Prime
Medicine,
Series
B,
Acquisition
Date:
4/19/21,
Cost $7,119 (1)(2)(3)
1,625,121‌
7,119‌
Ring
Therapeutics,
Series
B,
Acquisition
Date:
4/12/21,
Cost $9,004 (1)(2)(3)
978,705‌
9,004‌
Scribe
Therapeutics,
Series
B,
Acquisition
Date:
3/17/21,
Cost $6,219 (1)(2)(3)
1,027,755‌
6,219‌
Theseus
Pharmaceuticals,
Series
B,
Acquisition
Date:
2/9/21,
Cost $4,456 (1)(3)
514,797‌
5,838‌
Treeline,
Series
A,
Acquisition
Date:
4/9/21,
Cost $7,220 (1)(2)(3)
922,369‌
7,220‌
Total
Biotechnology
176,233‌
CONSUMER
NONDURABLES
0.2%
Healthcare
Services
0.2%
Capsule,
Series
D,
Acquisition
Date:
4/7/21,
Cost $12,364 (1)(2)(3)
853,213‌
12,364‌
Color
Health,
Series
D,
Acquisition
Date:
12/17/20,
Cost $11,181 (1)(2)(3)
296,922‌
13,596‌
Color
Health,
Series
D-1,
Acquisition
Date:
1/13/20,
Cost $9,358 (1)(2)(3)
438,696‌
20,088‌
Total
Consumer
Nondurables
46,048‌
LIFE
SCIENCES
0.7%
Life
Sciences
0.7%
Clear
Labs,
Series
C,
Acquisition
Date:
5/13/21,
Cost $13,294 (1)
(2)(3)
3,830,773‌
13,294‌
Element
Biosciences,
Series
C,
Acquisition
Date:
6/21/21,
Cost $17,704 (1)(2)(3)
861,217‌
17,704‌
Inscripta,
Series
E,
Acquisition
Date:
3/30/21,
Cost $12,829 (1)(2)
(3)
1,452,941‌
12,829‌
Lumicks
Tech,
Series
D,
Acquisition
Date:
4/14/21,
Cost $8,875 (1)(2)(3)
4,954‌
8,875‌
T.
ROWE
PRICE
Health
Sciences
Fund
9
Shares
$
Value
(Cost
and
value
in
$000s)
National
Resilience,
Series
B,
Acquisition
Date:
10/23/20,
Cost $16,458 (1)(2)(3)
1,204,832‌
53,507‌
National
Resilience,
Series
C,
Acquisition
Date:
6/9/21,
Cost $18,957 (1)(2)(3)
426,855‌
18,957‌
Total
Life
Sciences
125,166‌
PRODUCTS
&
DEVICES
0.1%
Capital
Equipment
0.0%
Reflexion
Medical,
Acquisition
Date:
4/3/20,
Cost $2,142 (1)(2)(3)
1,123,437‌
2,561‌
Reflexion
Medical,
Series
C,
1/2/24,
Acquisition
Date:
4/3/18,
Cost $4,243 (1)(2)(3)
2,507,885‌
5,718‌
8,279‌
Implants
0.1%
Kardium,
Series
D-5,
Acquisition
Date:
11/29/18,
Cost $8,574 (1)
(2)(3)(5)
8,849,057‌
8,989‌
Kardium,
Series
D-6,
Acquisition
Date:
1/8/21,
Cost $12,516 (1)
(2)(3)(5)
12,320,393‌
12,516‌
21,505‌
Total
Products
&
Devices
29,784‌
SERVICES
1.1%
Other
Services
1.0%
Caris
Life
Sciences,
Series
C,
Acquisition
Date:
8/14/20,
Cost $10,374 (1)(2)(3)
3,758,668‌
30,445‌
Caris
Life
Sciences,
Series
D,
Acquisition
Date:
5/11/21,
Cost $18,471 (1)(2)(3)
2,280,334‌
18,471‌
Freenome
Holdings,
Series
B,
Acquisition
Date:
6/24/19,
Cost $7,103 (1)(2)(3)
1,558,570‌
10,307‌
Freenome
Holdings,
Series
C,
Acquisition
Date:
8/14/20,
Cost $6,139 (1)(2)(3)
928,231‌
6,139‌
PrognomIQ,
Series
A-4,
Acquisition
Date:
11/15/19,
Cost $1,356 (1)(2)(3)(5)
593,540‌
1,356‌
PrognomIQ,
Series
A-5,
Acquisition
Date:
5/12/20,
Cost $1,174 (1)
(2)(3)(5)
513,797‌
1,174‌
PrognomIQ,
Series
B,
Acquisition
Date:
9/11/20,
Cost $8,533 (1)
(2)(3)(5)
3,734,140‌
8,533‌
Tempus
Labs,
Series
D,
1/2/24,
Acquisition
Date:
3/16/18,
Cost $8,876 (1)(2)(3)
946,886‌
53,000‌
Tempus
Labs,
Series
E,
Acquisition
Date:
8/23/18,
Cost $10,607 (1)(2)(3)
633,505‌
36,166‌
Tempus
Labs,
Series
F,
Acquisition
Date:
4/30/19,
Cost $4,279 (1)
(2)(3)
172,826‌
9,948‌
Tempus
Labs,
Series
G,
Acquisition
Date:
2/6/20,
Cost $4,284 (1)
(2)(3)
111,715‌
6,462‌
T.
ROWE
PRICE
Health
Sciences
Fund
10
Shares
$
Value
(Cost
and
value
in
$000s)
Tempus
Labs,
Series
G-2,
Acquisition
Date:
11/19/20,
Cost $6,720 (1)(2)(3)
117,271‌
6,720‌
188,721‌
Providers
0.1%
Honor
Technology,
Series
D,
Acquisition
Date:
10/16/20,
Cost $7,539 (1)(2)(3)
3,130,941‌
9,898‌
Honor
Technology,
Series
E,
Acquisition
Date:
9/29/21,
Cost $6,626 (1)(2)(3)
2,095,807‌
6,626‌
16,524‌
Total
Services
205,245‌
Total
Convertible
Preferred
Stocks
(Cost
$414,771)
582,476‌
PREFERRED
STOCKS
0.7%
LIFE
SCIENCES
0.7%
Life
Sciences
0.7%
Sartorius
(EUR) 
195,622‌
124,535‌
Total
Life
Sciences
124,535‌
Total
Preferred
Stocks
(Cost
$28,101)
124,535‌
SHORT-TERM
INVESTMENTS
0.2%
Money
Market
Funds
0.2%
T.
Rowe
Price
Government
Reserve
Fund,
0.05% (5)(7)
34,557,789‌
34,558‌
Total
Short-Term
Investments
(Cost
$34,558)
34,558‌
Total
Investments
in
Securities
100.3%
(Cost
$9,194,465)
$
19,340,134‌
Other
Assets
Less
Liabilities
(0.3)%
(51,806‌)
Net
Assets
100.0%
$
19,288,328‌
T.
ROWE
PRICE
Health
Sciences
Fund
11
Shares
are
denominated
in
U.S.
dollars
unless
otherwise
noted.
(1)
Non-income
producing
(2)
Level
3
in
fair
value
hierarchy.
(3)
Security
cannot
be
offered
for
public
resale
without
first
being
registered
under
the
Securities
Act
of
1933
and
related
rules
("restricted
security").
Acquisition
date
represents
the
day
on
which
an
enforceable
right
to
acquire
such
security
is
obtained
and
is
presented
along
with
related
cost
in
the
security
description.
The
fund
has
registration
rights
for
certain
restricted
securities.
Any
costs
related
to
such
registration
are
borne
by
the
issuer.
The
aggregate
value
of
restricted
securities
(excluding
144A
holdings)
at
period
end
amounts
to
$1,098,014
and
represents
5.7%
of
net
assets.
(4)
A
portion
of
the
position
represents
an
unfunded
commitment;
a
liability
to
fund
the
commitment
has
been
recognized.
The
fund's
total
unfunded
commitment
at
September
30,
2021,
was
$14,154
and
was
valued
at
$12,651
(0.1%
of
net
assets).
(5)
Affiliated
Companies
(6)
The
identity
of
certain
securities
has
been
concealed
to
protect
the
fund
while
it
completes
a
purchase
or
selling
program
for
the
securities.
(7)
Seven-day
yield
ADR
American
Depositary
Receipts
CHF
Swiss
Franc
CVR
Contingent
Value
Rights
DKK
Danish
Krone
EC
Escrow
CUSIP;
represents
a
beneficial
interest
in
a
residual
pool
of
assets;
the
amount
and
timing
of
future
distributions,
if
any,
is
uncertain;
when
presented,
interest
rate
and
maturity
date
are
those
of
the
original
security.
EUR
Euro
GBP
British
Pound
HKD
Hong
Kong
Dollar
JPY
Japanese
Yen
PIPE
Private
Investment
in
Public
Equity
SPAC
Special
Purpose
Acquisition
Company
T.
ROWE
PRICE
Health
Sciences
Fund
12
AFFILIATED
COMPANIES
($000s)
The
fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
1940
Act,
an
affiliated
company
is
one
in
which
the
fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
that
is
under
common
ownership
or
control.
The
following
securities
were
considered
affiliated
companies
for
all
or
some
portion
of
the
nine
months
ended
September
30,
2021.
Net
realized
gain
(loss),
investment
income,
change
in
net
unrealized
gain/loss,
and
purchase
and
sales
cost
reflect
all
activity
for
the
period
then
ended.
Affiliate
Net
Realized
Gain
(Loss)
Change
in
Net
Unrealized
Gain/Loss
Investment
Income
Doximity,
Class
$
—‌
$
27,028‌
$
—‌
Doximity,
Series
—‌
115,038‌
—‌
Helix
Acquisition,
Class
—‌
(614‌)
—‌
Immuneering 
—‌
4,638‌
—‌
Immuneering,
Series
—‌
17,427‌
—‌
Kardium,
Series
D-5 
—‌
415‌
—‌
Kardium,
Series
D-6 
—‌
—‌
—‌
Longboard
Pharmaceuticals 
(14‌)
(512‌)
—‌
Longboard
Pharmaceuticals,
Series
—‌
—‌
—‌
PrognomIQ,
Series
A-4 
—‌
—‌
—‌
PrognomIQ,
Series
A-5 
—‌
—‌
—‌
PrognomIQ,
Series
—‌
—‌
—‌
Seer ++
4,572‌
79,326‌
—‌
T.
Rowe
Price
Government
Reserve
Fund,
0.05%
—‌
—‌
16‌
Affiliates
not
held
at
period
end
—‌
(136,935‌)
—‌
Totals
$
4,558‌#
$
105,811‌
$
16‌+
T.
ROWE
PRICE
Health
Sciences
Fund
13
The
accompanying
notes
are
an
integral
part
of
this
Portfolio
of
Investments.
AFFILIATED
COMPANIES
(CONTINUED)
($000s)
Supplementary
Investment
Schedule
Affiliate
Value
12/31/20
Purchase
Cost
Sales
Cost
Value
09/30/21
Doximity,
Class
$
—‌
$
19,321‌
$
—‌
$
46,349‌
Doximity,
Series
*
—‌
—‌
158,793‌
Helix
Acquisition,
Class
*
—‌
—‌
6,308‌
Immuneering 
—‌
6,023‌
—‌
10,661‌
Immuneering,
Series
—‌
7,156‌
—‌
24,583‌
Kardium,
Series
D-5 
*
—‌
—‌
8,989‌
Kardium,
Series
D-6 
—‌
12,516‌
—‌
12,516‌
Longboard
Pharmaceuticals 
—‌
7,498‌
32‌
6,954‌
Longboard
Pharmaceuticals,
Series
4,157‌
—‌
4,157‌
—‌
PrognomIQ,
Series
A-4 
1,356‌
—‌
—‌
1,356‌
PrognomIQ,
Series
A-5 
1,174‌
—‌
—‌
1,174‌
PrognomIQ,
Series
8,533‌
—‌
—‌
8,533‌
Seer ++
15,584‌
—‌
4,078‌
90,832‌
Seer,
Class
136,935‌
—‌
—‌
—‌
T.
Rowe
Price
Government
Reserve
Fund,
0.05%
6,500‌
 ¤
 ¤
34,558‌
Total
$
411,606‌^
#
Capital
gain
distributions
from
mutual
funds
represented
$0
of
the
net
realized
gain
(loss).
++
Includes
previously
reported
affiliates
Seer
and
Seer,
Class
A
acquired
through
a
corporate
action.
+
Investment
income
comprised
$16
of
dividend
income
and
$0
of
interest
income.
¤
Purchase
and
sale
information
not
shown
for
cash
management
funds.
^
The
cost
basis
of
investments
in
affiliated
companies
was
$141,607.
*
On
the
date
indicated,
issuer
was
held
but
not
considered
an
affiliated
company.
T.
ROWE
PRICE
Health
Sciences
Fund
Unaudited
Notes
to
Portfolio
of
Investments
14
T.
Rowe
Price
Health
Sciences
Fund,
Inc. (the
fund) is
registered
under
the
Investment
Company
Act
of
1940
(the
1940
Act)
as
an
open-end
management
investment
company
and
follows
accounting
and
reporting
guidance
of
the
Financial
Accounting
Standards
Board
Accounting
Standards
Codification
Topic
946.
The
accompanying
Portfolio
of
Investments
was
prepared
in
accordance
with
accounting
principles
generally
accepted
in
the
United
States
of
America
(GAAP).
For
additional
information
on
the
fund’s
significant
accounting
policies
and
investment
related
disclosures,
please
refer
to
the
fund’s most
recent
semiannual
or
annual
shareholder
report
and
its
prospectus. 
VALUATION 
Fair
Value
  The
fund’s
financial
instruments
are
valued
at
the
close
of
the
New
York
Stock
Exchange
(NYSE),
normally
4
p.m.
ET,
each
day
the
NYSE
is
open
for
business,
and
are
reported
at
fair
value,
which
GAAP
defines
as
the
price
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date. The
T.
Rowe
Price
Valuation
Committee
(the
Valuation
Committee)
is
an
internal
committee
that
has
been
delegated
certain
responsibilities
by
the
fund’s
Board
of
Directors
(the
Board)
to
ensure
that
financial
instruments
are
appropriately
priced
at
fair
value
in
accordance
with
GAAP
and
the
1940
Act.
Subject
to
oversight
by
the
Board,
the
Valuation
Committee
develops
and
oversees
pricing-related
policies
and
procedures
and
approves
all
fair
value
determinations.
Specifically,
the
Valuation
Committee
establishes
policies
and
procedures
used
in
valuing
financial
instruments,
including
those
which
cannot
be
valued
in
accordance
with
normal
procedures
or
using
pricing
vendors;
determines
pricing
techniques,
sources,
and
persons
eligible
to
effect
fair
value
pricing
actions;
evaluates
the
services
and
performance
of
the
pricing
vendors;
oversees
the
pricing
process
to
ensure
policies
and
procedures
are
being
followed;
and
provides
guidance
on
internal
controls
and
valuation-related
matters.
The
Valuation
Committee
provides
periodic
reporting
to
the
Board
on
valuation
matters.
Various
valuation
techniques
and
inputs
are
used
to
determine
the
fair
value
of
financial
instruments.
GAAP
establishes
the
following
fair
value
hierarchy
that
categorizes
the
inputs
used
to
measure
fair
value:
Level
1
quoted
prices
(unadjusted)
in
active
markets
for
identical
financial
instruments
that
the
fund
can
access
at
the
reporting
date
T.
ROWE
PRICE
Health
Sciences
Fund
15
Level
2
inputs
other
than
Level
1
quoted
prices
that
are
observable,
either
directly
or
indirectly
(including,
but
not
limited
to,
quoted
prices
for
similar
financial
instruments
in
active
markets,
quoted
prices
for
identical
or
similar
financial
instruments
in
inactive
markets,
interest
rates
and
yield
curves,
implied
volatilities,
and
credit
spreads)
Level
3
unobservable
inputs
(including
the fund’s
own
assumptions
in
determining
fair
value)
Observable
inputs
are
developed
using
market
data,
such
as
publicly
available
information
about
actual
events
or
transactions,
and
reflect
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
Unobservable
inputs
are
those
for
which
market
data
are
not
available
and
are
developed
using
the
best
information
available
about
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
GAAP
requires
valuation
techniques
to
maximize
the
use
of
relevant
observable
inputs
and
minimize
the
use
of
unobservable
inputs.
When
multiple
inputs
are
used
to
derive
fair
value,
the
financial
instrument
is
assigned
to
the
level
within
the
fair
value
hierarchy
based
on
the
lowest-level
input
that
is
significant
to
the
fair
value
of
the
financial
instrument.
Input
levels
are
not
necessarily
an
indication
of
the
risk
or
liquidity
associated
with
financial
instruments
at
that
level
but
rather
the
degree
of
judgment
used
in
determining
those
values.
Valuation
Techniques 
Equity
securities,
including
exchange-traded
funds, listed
or
regularly
traded
on
a
securities
exchange
or
in
the
over-the-counter
(OTC)
market
are
valued
at
the
last
quoted
sale
price
or,
for
certain
markets,
the
official
closing
price
at
the
time
the
valuations
are
made.
OTC
Bulletin
Board
securities
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices.
A
security
that
is
listed
or
traded
on
more
than
one
exchange
is
valued
at
the
quotation
on
the
exchange
determined
to
be
the
primary
market
for
such
security.
Listed
securities
not
traded
on
a
particular
day
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices
for
domestic
securities
and
the
last
quoted
sale
or
closing
price
for
international
securities.
The
last
quoted
prices
of
non-U.S.
equity
securities
may
be
adjusted
to
reflect
the
fair
value
of
such
securities
at
the
close
of
the
NYSE,
if
the
fund
determines
that
developments
between
the
close
of
a
foreign
market
and
the
close
of
the
NYSE
will
affect
the
value
of
some
or
all
of
its
portfolio
securities.
Each
business
day,
the
fund
uses
information
from
outside
pricing
services
to
evaluate
and,
if
appropriate,
decide whether
it
is
necessary
to
adjust
quoted
prices
to
reflect
fair
value
by
reviewing
a
variety
of
factors,
including
developments
in
foreign
markets,
the
performance
of
U.S.
securities
markets,
and
the
performance
of
instruments
trading
in
U.S.
markets
that
represent
foreign
securities
and
baskets
of
foreign
securities. The
fund
uses
outside
pricing
services
T.
ROWE
PRICE
Health
Sciences
Fund
16
to
provide
it
with
quoted
prices
and
information
to
evaluate
or
adjust
those
prices.
The
fund
cannot
predict
how
often
it
will
use
quoted
prices
and
how
often
it
will
determine
it
necessary
to
adjust
those
prices
to
reflect
fair
value.
Investments
denominated
in
foreign
currencies
are
translated
into
U.S.
dollar
values
each
day
at
the
prevailing
exchange
rate,
using
the
mean
of
the
bid
and
asked
prices
of
such
currencies
against
U.S.
dollars
as
provided
by
an
outside
pricing
service.
Investments
in
mutual
funds
are
valued
at
the
mutual
fund’s
closing
NAV
per
share
on
the
day
of
valuation.
Investments
for
which
market
quotations
or
market-based
valuations
are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
as
determined
in
good
faith
by
the
Valuation
Committee,
in
accordance
with
fair
valuation
policies
and
procedures.
The
objective
of
any
fair
value
pricing
determination
is
to
arrive
at
a
price
that
could
reasonably
be
expected
from
a
current
sale.
Financial
instruments
fair
valued
by
the
Valuation
Committee
are
primarily
private
placements,
restricted
securities,
warrants,
rights,
and
other
securities
that
are
not
publicly
traded.
Factors
used
in
determining
fair
value
vary
by
type
of
investment
and
may
include
market
or
investment
specific
considerations.
The
Valuation
Committee
typically
will
afford
greatest
weight
to
actual
prices
in
arm’s
length
transactions,
to
the
extent
they
represent
orderly
transactions
between
market
participants,
transaction
information
can
be
reliably
obtained,
and
prices
are
deemed
representative
of
fair
value.
However,
the
Valuation
Committee
may
also
consider
other
valuation
methods
such
as
market-based
valuation
multiples;
a
discount
or
premium
from
market
value
of
a
similar,
freely
traded
security
of
the
same
issuer;
discounted
cash
flows;
yield
to
maturity;
or
some
combination.
Fair
value
determinations
are
reviewed
on
a
regular
basis
and
updated
as
information
becomes
available,
including
actual
purchase
and
sale
transactions
of
the
investment.
Because
any
fair
value
determination
involves
a
significant
amount
of
judgment,
there
is
a
degree
of
subjectivity
inherent
in
such
pricing
decisions,
and
fair
value
prices
determined
by
the
Valuation
Committee
could
differ
from
those
of
other
market
participants.
Valuation
Inputs
  The
following
table
summarizes
the
fund’s
financial
instruments,
based
on
the
inputs
used
to
determine
their
fair
values
on
September
30,
2021
(for
further
detail
by
category,
please
refer
to
the
accompanying
Portfolio
of
Investments):
T.
ROWE
PRICE
Health
Sciences
Fund
17
Following
is
a
reconciliation
of
the
fund’s
Level
3
holdings
for
the
period ended
September
30,
2021.
Gain
(loss)
reflects
both
realized
and
change
in
unrealized
gain/
loss
on
Level
3
holdings
during
the
period,
if
any.
The
change
in
unrealized
gain/loss
on
Level
3
instruments
held
at
September
30,
2021,
totaled $80,099,000 for
the
period ended
September
30,
2021.
In
accordance
with
GAAP,
the
following
table
provides
quantitative
information
about
significant
unobservable
inputs
used
to
determine
the
fair
valuations
of
the
fund’s
Level
3
assets,
by
class
of
financial
instrument.
Because
the
Valuation
Committee
considers
a
wide
variety
of
factors
and
inputs,
both
observable
and
unobservable,
in
determining
fair
values,
the
unobservable
inputs
presented
do
not
reflect
all
inputs
significant
to
the
fair
value
determination.
($000s)
Level
1
Level
2
Level
3
Total
Value
Assets
Common
Stocks
$
17,423,858‌
$
1,113,289‌
$
61,418‌
$
18,598,565‌
Convertible
Preferred
Stocks
—‌
5,838‌
576,638‌
582,476‌
Preferred
Stocks
—‌
124,535‌
—‌
124,535‌
Short-Term
Investments
34,558‌
—‌
—‌
34,558‌
Total
$
17,458,416‌
$
1,243,662‌
$
638,056‌
$
19,340,134‌
($000s)
Beginning
Balance
12/31/20
Gain
(Loss)
During
Period
Total
Purchases
Total
Sales
Ending
Balance
9/30/21
Investment
in
Securities
Common
Stocks
$
87,007‌
$
375‌
$
51,575‌
$
(77,539‌)
$
61,418‌
Convertible
Preferred
Stocks
424,227‌
13,244‌
263,014‌
(123,847‌)
576,638‌
Total
$
511,234‌
$
13,619‌
$
314,589‌
$
(201,386‌)
$
638,056‌
T.
ROWE
PRICE
Health
Sciences
Fund
18
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Common
Stock
$
61,418‌
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
Uncertainty
1%-59%
30%
Decrease
Market
comparable
Enterprise
Value
to
Sales
Multiple
4.8x
21.8x
14.1x
Increase
Sales
Growth
Rate
11%-42%
29%
Increase
Enterprise
Value
to
Gross
Profit
Multiple
9.5x
15.4x
12.5x
Increase
Gross
Profit
Growth
Rate
13%
13%
Increase
Discount
for
Lack
of
Marketability
10%
10%
Decrease
Estimated
Liquidation
Value
Discount
for
lack
of
collectability
100%
100%
Decrease
Convertible
Preferred
Stocks
$
576,638‌
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
Cumulative
Preferred
Dividend
Rights
0%
-
2%
2%
Decrease
T.
ROWE
PRICE
Health
Sciences
Fund
19
#
No
quantitative
unobservable
inputs
significant
to
the
valuation
technique
were
created
by
the
fund’s
management.
*
Unobservable
inputs
were
weighted
by
the
relative
fair
value
of
the
instruments.
**
Represents
the
directional
change
in
the
fair
value
of
the
Level
3
investment(s)
that
would
have
resulted
from
an
increase
in
the
corresponding
input
at
period
end.
A
decrease
in
the
unobservable
input
would
have
had
the
opposite
effect.
Significant
increases
and
decreases
in
these
inputs
in
isolation
could
result
in
significantly
higher
or
lower
fair
value
measurements.
+
Valuation
techniques
may
change
in
order
to
reflect
management’s
judgment
of
current
market
participant
assumptions.
F114-054Q3
09/21 
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Premium
for
Cumulative
Preferred
Dividend
Rights
0%
-
1%
1%
Increase